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2 ABSTRACT
Patients who develop peritoneal metastases are usually regarded as
entering a terminal stage of cancer disease progression, have poor prognosis and
rarely benefit from surgery. Unfortunately little is known about the molecular
mechanisms underlying peritoneal metastasis, but it seems likely that such
mechanisms maybedistinct from those of haematogenous metastatic spread. It
was hypothesised that by correlating the patterns of gene expression of different
malignant cells invading the peritoneum with their differing microscopic
behaviour, it might be possible to define genes of particular mechanistic
importance in the developmentof peritoneal metastasis.
A three-dimensional model of peritoneum was constructed from human
mesothelial cells, fibroblasts and rat-tail collagen. Highly metastatic gastric
cancer cells (TMK I, KATOIII) or colonic cancer cells with low metastatic
potential (SW480, HT 29) were seeded onto this 3-D model. After seven days
invasion was assessed by light microscopy and immunocytochemistry. Cancer
and neighbouring mesothelial cells were removed from the models by laser
capture microdissection. Messenger RNA was extracted from both cancercells
and mesothelial cells, and amplified, labelled and hybridised on microarrays
spotted with oligonucleotides representing 1853 cancer-associated genes. Genes
for which mRNAlevels correlated with the degree of invasion wereselected, to
identify those from both tumour and ‘host’ mesothelial cells that were most
likely to be involved in common pathophysiological pathways of peritoneal
metastasis and invasion. Using this approach five cancer cell genes were
identified in which expression levels was associated with degree of invasion
(four progressively up-regulated and one down-regulated). Eighteen mesothelial
cell genes (Fifteen up-regulated and three down-regulated) were similarly related
to degree of invasion by the cancer cells. Functional annotation of the candidate
genes identified revealed that they span a variety of relevant biological functions
including apoptosis, calcium metabolism, tumour suppression, cell cycle and
adhesion. The results suggest further similar studies are likely to be highly
informative, particularly in relation to the modification of the host cell response
in the peritoneum.
3 INTRODUCTION
3.1 CHARACTERISTICS OF THE NORMAL PERITONEUM
The peritoneum is a serous membranewhichlines the abdominalcavity.Its
nameis derived from the Greek word “peritonaion” meaning to stretch around.
The peritoneal cavity is the potential space between the parietal peritoneum
(which lines the abdominal cavity) and the visceral peritoneum (the inner layer
which closely covers the organs and includes the mesenteries). Its surface is
covered by a single layer of mesothelial cells, the mesothelium. This type of
epithelium is mesodermal in origin. Like all epithelia the mesothelium is
separated from underlying tissues by a basement membrane that provides
structural support as well as binding the mesothelium to the underlying
supporting tissue. The mesothelial basement membraneis also involved in the
control of mesothelial growth and differentiation and forms an impenetrable
barrier to mesothelial cell growth into the deeper connective tissue layer. The
peritoneum functions as a gliding, non-adhesive surface for the internal organs
and as a selective barrier, regulating transport of fluid and solutes between the
circulation and the body cavity (R.M.H.McMinn,1994).
Characteristic features of the mesothelial cells include: broad cytoplasmic
extensions with numerous microvilli, micropinocytotic vesicles concentrated at
the surface of the cells and around the Golgi apparatus, intracellular storage
organelles called lamellar bodies, cytoplasm containing many free ribosomes,
abundant rough endoplasmic reticulum, numerous mitochondria and a well
developed Golgi apparatus. Mesothelial cells have a high synthetic and secretory
capacity. They are a major source of prostaglandins, cytokines and phospholipids
in the peritoneal cavity, synthesize and secrete various pro and anti inflammatory
cytokines, and locally contribute to the fibrinolytic cascade (Stylianou, Jenneret
al., 1990).
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3.2. DEFINITION OF PERITONEAL METASTASIS
The term peritoneal metastasis was first described by Sampson in 1931 to
describe the intra-abdominalspread of ovarian carcinoma. Peritoneal metastases
take place when tumours seed cells in the peritoneal cavity, leading to the
formation ofascitic fluid or metastatic deposits. Although ovarian tumoursare a
commonsource of peritoneal metastasis, neoplasms of the gastrointestinal tract
(oesophagus, stomach, liver, pancreas, small intestine and colon) may also
invade the peritoneum (Jayne, 2003).
While some patients have marked symptoms from peritoneal metastases
such as abdominal pain and ascites, others may be asymptomatic at the time of
diagnosis. Regardless, the presence of peritoneal metastasis denotes a late stage
of disease progression, and numerous reports confirm that such patients have
poorer prognosis and generally do not benefit from surgery (Yoshikawa, Kanari
et al., 2003a).
3.3 EPIDEMIOLOGY, TUMOUR CLASSIFICATION AND PROGNOSIS
Most tumours able to metastasise to the peritoneum are common in the
western world, particularly in the UK. Those patients developing peritoneal
metastasis will ultimately die of the disease (Yoshikawa, Kanari et al., 2003b).
Although incidence and mortality figures for individual tumours are available in
national databases, the true overall incidence of peritoneal metastasis 1s
unknown. Howeverindividual figures published by some authorities reflect the
high mortality of this disease. Some neoplasmsare morelikely to metastasise in
the peritoneum, such as oesophagus and pancreas, which carry very high
mortality rates. However, other common cancers, such as bowel, may
metastasise directly to the liver instead. At present, reliable factors which predict
peritoneal metastasis have not been identified. The following tables show the
incidence of peritoneal metastasis from primary and recurrent gastrointestinal
tumoursandtheir mortality
11
 ORIGIN PRIMARY RECURRENCE SOURCE
Stomach 40% 60% (Kobayashi, Tsuburayaet al., 2006)
Colon 5-10% 20-50% (Culliford, Brookset al., 2001)
Pancreas 40-60% N/A (Nakao, Fujii et al., 2006)
Oesophagus 17% N/A (Chau, Normanetal., 2004)
Table 1 Incidence of peritoneal metastasis from gastrointestinal tumours.
(Primary) indicates initial diagnosis. In the presence of recurrent disease
peritoneal metastases are more likely and they may be the modeofpresentation.
(N/A) No available figures were found for recurrent disease for oesophageal and
pancreatic cancers, both of which have overall mortality of over 90% at 12
months from the momentof diagnosis.
 ORIGIN MEDIAN SURVIVALIN SOURCE
MONTHS
Stomach 8.9 (Shiraishi, Sato et al., 2007)
Colon Less than 12 (Assersohn, Normanetal.,
1999;Mahteme, Hanssonetal., 2004)
Pancreas 2.7 (Yonemori, Okusakaetal., 2007)
Table 2 Although overall mortality figures for peritoneal metastasis are not
available some studies report survival in months, with disease progression and
survival of less than 12 monthsfor colorectal cancer, 8.9 for gastric cancer and as
little as 2.7 months for pancreatic cancer. No figures were available for
oesophageal cancer.
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As mentioned already a number of primary tumours, affecting various
organs in the abdomen,can spread into the peritoneal cavity and cause metastatic
lesions.
Bowelcancer is second most commoncancerin females (11%), and the
third most common in males (14%) (Source: www.statistics.gov.uk). In North
America and Western Europe this remains the second commonest cause of
cancer death. Surgery still remains the only curative treatment (Dorudi, Steele et
al., 2002).
The incidence of gastric cancer increases from the fifth decade oflife
reaching its peak at the seventh. Its incidence is low in Western Europe. Overall
mortality rates are high and relatively unchanged overthe past 30 years (Dicken,
Bigam et al., 2005). In the United Kingdom, gastric cancer is the fifth most
common cancerin males and ninth in females (Source: www.statistics.gov.uk).
The incidence of oesophageal cancer has rapidly increased in the UK.
Adenocarcinomais now more frequent than squamouscell carcinoma. Being the
sixth most common malignancy in males andthirteenth in females, the five year
mortality is over 80% (Source: www:statistics.gov.uk). Patients suffering with
Barrett’s oesophagus are particularly at risk (Fitzgerald, 2004). 50% of newly
diagnosed patients will present with metastatic disease and a vast majority of the
remaining 50% will developit (Ilson, 2003).
Pancreatic canceris the eleventh most commonly diagnosed cancerin the
UK, seventh most common in females, and less than 3% of males (Source:
www:.statistics.gov.uk). However, it is the sixth most common type of cancer
death. The late presentation with advanced disease is responsible for the overall
median survival of less than six months (Alexakis, Halloran et al., 2004).
Ovarian cancer is the fourth most commoncancer diagnosed in females
in UK (Source: www:statistics.gov.uk). Incidence is increasing in some Eastern
and Southern European countries (Bray, Loos et al., 2005). Family history of
ovarian or breast cancer and mutations in the BRCA-1 and BRCA-2 genes are
correlated to the disease (Bertone-Johnson, 2005). The risk is reduced by high
parity and use of oral contraceptives (Parkin, Bray et al., 2005). The 5 year
survival rates for advanced disease are approximately 20-25% (Ozols, 2005).
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Other far less common tumours, which may metastasise into the
peritoneum, include primary liver cell carcinoma, small intestinal tumours and
carcinomaofthe gallbladder (Source: www:statistics.gov.uk).
3.4 CURRENT VIEWS IN THE MANAGEMENTOF PERITONEAL
METASTASIS
The managementof peritoneal metastatic disease from gastrointestinal
cancer has been discussed in a number of studies. Numerous drugs and
antibodies have been tested, and only a few patients have obtained a marginal
survival benefit. No studies have conclusively shown long term survival benefits.
Mostof the available research up to date has been on advancedgastric cancer
and the most successful treatments are described below.
The agent that has shown the most potential is an oral fluoropyrimidine
which acts as inhibitor of DNA synthesis, called S-1. Sasaki published a
systematic review of various studies, where S-1 was used alone or in
combination therapy with 5-fluorouracil (antimetabolite drug) for advanced
gastric cancer and peritoneal metastasis. The study showed that this drug could
be a key in the treatmentof the disease (Sasaki, 2003). Kitamura et al published a
small pilot study with 31 patients with gastric cancer and peritoneal metastasis.
They were treated with S-1 until disease progression or withdrawal from the
regime. Median survivals of up to 12 months were reported (Kitamura, Hayashi
et al., 2003). The literature also contains a few promising case studies. Tamura et
al reported one case of recurrent gastric cancer with peritoneal metastasis treated
with a combination of paclitaxel (pro-apoptotic and anti-angiogenic factor from
the taxane group) and S-1. The patient had survived nearly two years up to the
time of publication (Tamura, Miki et al., 2006). Kobayashi et al reported a
patient with advanced gastric cancer and peritoneal metastasis who survived
more than two yearsafter treatment with S-1 (Kobayashi, Konishiet al., 2002) In
a study conducted by Ishizoneet al, sixteen patients with peritoneal metastases
from gastric cancer where treated with S-1. They showedsignificantly longer
median survival times (median=550) days than the 25 patient control group
(median=215 days) (Ishizone, Maruta et al., 2006). Saikawa et al conducted a
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phase II trial including 13 patients with unresectable gastric cancer, 3 of them
with peritoneal metastases, using S-1 with cisplatin and radiotherapy. Peritoneal
dissemination disappearedin all 3 patients (Saikawa, Kubotaet al., 2008).
Other chemotherapy regimes have been attempted for the management of
peritoneal metastases. Fukasawa and Yokoyama reported a patient with
peritoneal carcinomatosis treated with paclitaxel in combination with
fluorouracil; she was still alive after 25 months (Fukasawa, Shoji et al.,
2006;Yokoyama, Tazawaet al., 2005). A multicenter study, phase II, published
by Takiuchi et al (Takiuchi, Goto et al., 2008) used paclitaxel in combination
with doxifluridine (intermediate metabolite of capecitabine) and fluorouracil for
the treatment of patients with advanced and recurrent gastric cancer who had
previously been treated with S-1 for 4 or more weeks. 8 out of the 35 patients
involved in the study had peritoneal metastases. Unfortunately this regime did
not provide any addedbenefit in terms of survival rates.
Intraperitoneal hyperthermic therapy is another avenue previously tried,
but unfortunately unsuccessful. In one study with 103 patients this technique was
combined with intraperitoneal Mitomycin C (cytotoxic antibiotic). Although
significant survival rates were observed in patients with gastric cancer stage III
(serosal invasion, peritoneal seeding) no significant difference was observed in
stage IV disease (peritoneal and distant metastasis). All patients eventually
developed recurrence (Kim & Bae, 2001). Sugarbaker et al combined
peritonectomy and intraperitoneal hyperthermic therapy in patients with gastric
cancer and peritoneal metastasis (Yonemura, Kawamura et al., 2004). The
median survival was 16 months and 87% of patients died of disease progression
at 46 months.
Someof the above results are encouraging, and they show some short term
benefits in term of survival even though long term figures remain unchanged.
However it is difficult to assess how strong is the effect of different
chemotherapy regimes on patients with peritoneal metastasis. This is because
most studies compare treatment regimes for the management of advancedcancer,
where patients included may have metastases to lymph nodes, peritoneum and
distant metastases. Stratification of these patients is complex. Often they present
with disease in more than one location, such as the liver, lung and peritoneum.
Subsequentlyit is difficult to assess what effect, in terms of survival, would the
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treatment havein those patients if they had peritoneal disease only. Furthermore,
it is difficult to assess whether patients with widespread metastatic and peritoneal
disease could have better survival rates if peritoneal metastasis was not present.
Morerobust answers to the managementof peritoneal metastasis could be drawn
from multi-centre randomised controlled trials where the treatment arm included
patients with primary tumour and peritoneal metastasis only and the control
group included patients with primary tumouronly.
At present it may be concluded that there is not enough evidence for the
management of peritoneal metastasis and effects on patient survival. More
research is required into the underlying molecular mechanisms of peritoneal
disease in these advanced cancers, in the hope that new rational and effective
treatments can be developed.
3.5 MOLECULAR BIOLOGY OF PERITONEAL METASTASIS
3.5.1 GENERAL STEPS IN THE METASTATIC CASCADE
The process of metastasis is thought to involve a series of linked
sequential steps involving multiple tumour-host interactions (Meyer & Hart,
1998). Having disengaged from its primary site the metastatic tumour must pass
through the surrounding stroma and enter the vasculature or lymphatic system, or
seed in a body cavity. The tumourcell must be able to survive these different
environments and whensettled at a distant site it can then extravasate or invade
into the target organ interstitium and parenchyma. The numerous
interconnections between the lymphatic and vascular compartments may allow
disseminating tumour cells to transit between these two systems. After
establishing an adequate blood supply, the metastatic cell may proliferate and
develop into a secondary mass (Ahmad & Hart, 1997). All these steps are
summarisedin the following diagram (Fig 1):
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HAEMATOGENOUS METASTASIS PERITONEAL METASTASIS
 
Initial transforming eventb
Growth of neoplastic cells&
Neovascularisation/angiogenesis of the tumour©Detachmentof neoplastic cells from primary tumour3
Localinvasion of extracellular matrix by tumourcellsjsIntravasation of tumourcells into lymphatics
or vasculatureos
Initial transforming event
Growth of neoplastic cellsaa
Neovascularisation/angiogenesis of the tumour
Detachmentof neoplastic cells from primary tumour
O
Neoplastic cell adhesion to the mesothelial layer~S
Peritoneal seeding
without invasion
Peritoneal invasion
Survival of tumourcells in circulation
and avoidance of immuneattack
Figure 1 The characteristics of haematogenous
metastasis and peritoneal metastasis are shown. A critical
difference between both processes is that tumour cells
gl may or may not have the ability to invade, once in the
peritoneum
Extravasation of tumourcells from vasculature
into secondary organ tissue  Survival and proliferation within organ parenchyma
3.5.2 SPECIAL FEATURES OF PERITONEAL METASTASIS
As mentioned above, neoplasms can invade natural body cavities such as
the pleura or the peritoneum by direct seeding, thus by-passing the circulation
and it seemslikely that the mechanisms for metastatic spread via this route are
somewhat different from the better characterised process of haematogenous
metastasis. Once the tumourcells separate from a primary abdominal tumour,
they can disseminate throughout the abdominal cavity and adhere to the
mesothelial layer. They may then invade the mesothelium and its basement
membranethus gaining access to the underlying stroma. Tumourcells can then
proliferate and induce angiogenesis in order to survive. Interestingly, intra-
peritoneal tumour spread may take the form of simply glazing all peritoneal
surfaces without invasion of the underlying parenchyma of the abdominal
organs. This raises the idea of “seed and soil”, which considers the ability to
reimplant and the capacity to invade as different patterns of cell behaviour. This
concept wasfirst defined by the experiments of Souter et al (Souter, Wells et al.,
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1985), who reported that the placement of peritoneal venous shunts to control
symptoms in women with ascites due to ovarian cancer did not result in
metastases in other organs. This was in spite of the presence of millions of
tumourcells from the peritoneal cavity being introducedinto the circulation via
the shunt. Thus, ovarian cancer cells were unable to “seed”. They were not
competent to invade distant organs and establish metastases from the blood.
Furthermore these cells were metastatic in the peritoneum but not in the
circulation confirming that the mechanisms involved in the two processes have
some key differences. However, other neoplasms such as gastrointestinal
carcinomascan penetrate the wall of the viscus, reimplant and invadeat distant
sites in the peritoneal cavity. A similar sequence occurs with lung cancers in the
pleural cavities.
Clinically, tumours originating in the same organ and from the same
histopathological type behave remarkably similarly, especially for the
distribution of haematogenousmetastasis. The distribution of metastases follows
a reproducible pattern, which can often be explained by the anatomical location
of a neoplasm e.g. Colon tumours invade locally and metastasise primarily to
draining lymph nodesandthen liver. However anatomical drainage may not be
the only reason for the location of metastases in specific organs. Metastases
derived from breast carcinomasthat appear in bone must do so by bypassing the
lung as do prostate metastases to the skull or colon metastases to brain (Frost &
Levin, 1992). These are known as skip metastases and represent a convincing
illustration of the importance of the host factors in determining where and how
easily metastases can develop.
An as yet poorly understood issue in the development of peritoneal
metastases is the role played by the peritoneum, in preventing or protecting
against metastasis formation. It is unclear whether the mesothelium or basal
membraneor both can, to a certain extent, protect the underlying tissues against
invading cells. A number of publications have reported correlation between
peritoneal disruption caused by surgical traumaand increased incidence of loco-
regional cancer recurrences (van den Tol, van Rossenet al., 1998;van den,ten et
al., 2005). These results suggest that the peritoneum may, in some way, act as a
physical barrier against invasion. However, there are unanswered questions about
whether the mesothelial cells themselves have a particular role in limiting cancer
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spread e.g. through direct cellular interactions with cancercells, or indirectly via
locally produced cytokines.
Althoughit is generally understood that neoplasms with worse histological
grade, i.e. poorly differentiated, are more likely to metastasise, there are no
studies, clearly correlating histological grade and peritoneal metastasis. Some
histological types of a given tumour are more likely to invade peritoneum e.g.
oesophageal and gastric carcinoma overall more invasive than colorectal
neoplasms; but while histology may provide information about cell behaviour
(abundance of mitotic counts and nuclear pleomorphism)andtissue architecture,
it does not provide specific information about the potential for peritoneal
metastasis.
3.6 CELLULAR PROCESSESIN PERITONEAL METASTASIS
Close anatomic interaction over time between cancercells and host cells,
via numerous molecules is essential for the metastatic process to occur.
Adhesion, extracellular matrix (ECM) degradation or proteolysis, angiogenesis,
cell signalling, tumour suppression, cell cycle control, apoptosis and other
functions have been described in blood-borne metastasis. The role of these
mechanismsis far less well understood in peritoneal metastasis. A review of
molecules and their functions is provided below.
3.6.1 EXTRACELLULAR MATRIX PROTEOLYSIS
Collagens, laminins, fibronectins and elastins are components of the
extracellular matrix (ECM) which can be degraded by a numberofproteases.
Metalloproteinases are one group of these extracellular proteases which have a
role in cancer metastasis, as well as many other cellular processes. At least 20
human MMPshavebeenidentified. These enzymeshave both a descriptive name
and an MMP number. Commonfeatures in all MMPs include a pre- domain
whichis a signal peptide for secretion, a pro- domain, important for maintaining
latency, a catalytic domain with a highly conserved Zinc binding site and a
haemopexin like domain. Most MMPsaresecreted in the latent form. However a
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few of them have a transmembrane domain and remain attached to the
membrane.
The role of MMPsin neoplasia wasfirst described by Liotta et al in the
early 80s when ECM proteolysis was identified as one of the basic steps in
invasion (Liotta, Tryggvason et al., 1980). Further in vitro studies have shown
that the MMPsare capable of degrading a wide range of connective tissue
proteins, indicating that these enzymes mayplay a role in connective tissue
destruction and remodelling associated with cancer invasion and metastasis (Ye,
2000). Murray et al studied the metalloproteinases andtheir tissue inhibitors in a
series of 74 gastric cancers, most of which were advanced gastric cancers.
MMP2 was consistently found in tumour cells, but not in adjacent gastric
epithelium. However no such association was seen with MMPI (Curran &
Murray, 2000). Otani et al found that the MMPI gene was over-expressed in
stromal cells around cancer nests, particularly at the margins of invasion, but
there was no definite pattern of expression among cancercells (Otani, Okazaki et
al., 1994). These findings indicate that raised levels of MMPI associated with
tumour invasion and metastasis. Moreover Inoue et al studied the relationship
betweengastric cancer cells, MMP1 expression and peritoneal metastasis (Inoue,
Yashiro et al., 1999). They found significant association between MMPI
expression and peritoneal metastasis. It was suggested that MMP1 could have a
role as prognostic factor MMP2is well known as a decomposing enzymeof type
IV collagen, laminin and fibronectin, which are all components of the basement
membrane, and its relationship to the degree of cell differentiation and the
potential for invasion and metastasis has been reported. Mizutani et al used an
artificial model of peritoneum (matrigel) to study MMP1 and MMP2expression
when in contact with gastric cancer cells, and whether such expressions would
result in enhanced cancer invasion. MMPI derived from peritoneal cells was
found to be involved in local invasion and peritoneal dissemination of gastric
cancer. (Mizutani, Kofuji et al., 2000a). Yoshikawaet al (Yoshikawa, Tsuburaya
et al., 2000) found significantly higher levels of circulating tissue inhibitor of
metalloproteinase (TIMP) | in patients with peritoneal disease. In their studies
they found that although less sensitive than laparoscopy and cytology, plasma
TIMP1 levels werebetter to predict peritoneal dissemination than other markers.
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Yonemura et al suggested that MMP-7 may play an important role in
peritoneal dissemination as they managed to stop MKN-45 P cells from
proliferating in a peritoneal model after introducing Antisense oligonucleotides
complementary to exon 3 of the MMP-7 mRNA (Yonemura, Endoet al., 2001).
Some novel approaches in the management of metastatic disease with
inhibitors of metalloproteinases have been developed (Hoekstra, Eskens etal.,
2001). Aparicio et al have successfully prevented the developmentofperitoneal
metastasis in rat models by treating them with Batimastat, a synthetic MMP
inhibitor (Aparicio, Kermorgantet al., 1999). Similar results were reported by
Giavazzi et al who reported positive results by the administration of Batimastat
combinedto cisplatin (Giavazzi, Garofaloet al., 1998). Aslam et al commenced a
trial of Batimastat for the management of malignant ascites. After intraperitoneal
injection of the drug, less accumulation of ascitic fluid was reported; overall
tolerance was good and overall survival was up to 112 days. At the time of
publication the cohort was not large enough, nevertheless the results were
encouraging (Aslam & Marino, 2001).
3.6.2 ADHESION
Cells detect their extracellular milieu through interactions employing a
variety of cell adhesion molecules. They interact with extracellular matrix
components via integrins and syndecan molecules, and with adjacent cells via
membersofthe cadherin, selectin and ICAM families.
3.6.2.1 ICAM
Intercellular adhesion molecules are cell surface glycoproteins that are
important in cell to cell and cell to extracellular matrix interactions (Tempia-
Caliera, Horvath et al., 2002). There are five intercellular adhesion molecules
(ICAM) known in humans. They all have two to nine extracellular
immunoglobulin-like domains thus making them members of the
immunoglobulin superfamily (Ihanus, Uotila et al., 2003). ICAM-1, also known
as CD54 has 5 extracellular immunoglobulin like domains and serves a role in
promoting adhesion in inflammatory and immunereactionsis also a ligand for
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leukocyte function antigen (LFA-1, CD1la, CD18) , which is an a8 complex,
member of the integrin family of cell-cell and cell-matrix receptors mediating
various cell to cell interactions involved in immunity. ICAM-2 has two
extracellular domains, one of whichis also a ligand for LFA-1 (Kaihara, Iwagaki
et al., 1998).
ICAM-1 has been reported to be secreted by tumour cells in order to
promote the invasion of organs such as liver, thyroid, ovary, stomach, colon,
bladder and pancreas. Tempia-Caliera et al demonstrated high expression levels
of ICAM-1 and VCAM-1in pancreatic cancer cells by immunohistochemistry
(Tempia-Caliera, Horvath et al., 2002). Alexiou et al found increased serum
levels of these adhesion molecules in patients with colonic cancer. There was
correlation between serum levels, cancer stage and the presence of lymph nodes
and distant metastases (Alexiou, Karayiannakis et al., 2001). Yasuda et al
demonstrated in their study that ICAM-1 was down-regulated by a signalling
mechanism involving {1 integrin, thus inhibiting adhesion of lung cancercells to
T cells and preventing their recognition and elimination (Yasuda, Tanakaet al.,
2001).
3.6.2.2 CADHERINS AND CATENINS
Cadherins are transmembrane glycoproteins with an extracellular region
composed of four repeat domains, a transmembrane domain and a short
cytoplasmic domain, which is the most highly conserved region. The
cytoplasmic tails of functional cadherins associate with accessory cytoplasmic
proteins (catenins) that mediate binding to the actin cytoskeleton. The catenin
complex consists of a-catenin, B-catenin and y-catenin. The extracellular N-
terminal end is essential to the process of homophylic calcium dependentcell-
cell adhesion. Deletion of the cytoplasmictail or modification of the catenin will
abrogate cadherin function. Thus cadherins and catenins have a major role in
regulating adhesive activity and alteration of their function or expression is a
crucial step in the process of metastasis formation (Meyer & Hart, 1998).
The cadherin family contains several members, including E-cadherin
which is involved in epithelial cell-cell adhesion. Levels of E-cadherin are often
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down-regulated in malignant cells, and re-expression of E-cadherin in suchcells
has a tumoursuppressoreffect.
Oka et al (Oka, Shiozaki et al., 1992) studied 103 gastric tumours using
immunohistochemistry. There were 11 cases of peritoneal metastasis, and 9 of
them showed significantly reduced expression of E-cadherin, compared to non-
metastatic tumours, thus suggesting that reduced expression of E-cadherin may
be relevant to invasion and metastasis.
Yonemura et al (Yonemura, Endou et al., 2000) analysed E-cadherin
mRNA andprotein expression in clinical specimens of primary gastric cancers
and gastric cancer cell lines. They found that 88% of differentiated
adenocarcinomas and 50 % of poorly differentiated adenocarcinomas expressed
E-cadherin (p=0.0015). However nosignificant differences were found in those
with or without liver, lymph nodeor peritoneal metastasis. Hedge et al (Hegde,
Qi et al., 2001) used microarray technology to identify genes relevant to
metastasis in colorectal cancer. They found no significant changes in the pattern
of expression of homotypic cell adhesion molecules. However, gross
abnormalities were found in expression of genes involved in the formation of
cytoskeletal architecture and the extracellular matrix. Toyoda et al (Toyoda, Doi
et al., 2005) compared the expression of cadherins and catenins of seven human
pancreatic cancercell lines. Increased expression of E-cadherin and catenins was
found in all but one cell line. Two cell lines with increased expression were
metastatic.
The above studies were performed in different centres with different
sources and materials and the results are conflicting. Almost every author
reported changes in expression but correlation between adhesion molecule
expression across studies is almost nonexistent.
3.6.2.3 INTEGRINS
Integrins comprise a diverse family of receptors that mediate adhesion
between the cell membrane and the extracellular matrix or other cell adhesion
molecules, ICAMs. They are composed of two non-covalently associated a and B
subunits and the combination of 8 B subunits with 14 a subunits generates an
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heterogeneous family of over 20 heterodimers (Hynes, 1992). The majority of
integrins mediate cell-matrix interactions during cell migration, by binding to
components of the basement membrane and interstitial stroma, including
fibronectin, laminin, thombospondin, vitronectin and collagens so that manycell
types expressing several different integrins can bind to several of these
extracellular proteins. However, some integrins which are expressed on
lymphocytes and leukocytes mediate heterophilic cell-cell adhesion. This
process, so important for the extravasation of leukocytes at sites of inflammation,
is mimicked by certain tumour types in the analogous process of metastatic
extravasation (Ahmad & Hart, 1997;Meyer & Hart, 1998).
Interactions between tumourcells and the ECM occur during theinitial
invasive action of metastatic cells. Changes in adhesive properties of malignant
cells, in co-operation with increased proteolytic activity around tumourcells are
extremely important events in mediating some of the changes involved in
metastatic progression.
Ura et al (Ura, Dennoet al., 1998) examined the correlation between the
expression of «281 and a3f1 integrins and the clinicopathological features of
gastric cancer, focusing particular attention on the different types of metastases.
18 out of 110 patients had peritoneal metastases. Specimens were tested by
immunohistochemistry using anti-integrin monoclonal antibodies. They
concluded that the expression of a3 subunit was directly related to the presence
of peritoneal metastasis (p<0.0005)
In a different study, with sections from 121 malignant effusions and 30
corresponding primary and metastatic lesions from ovarian tumours protein
expression of av and 61 integrin subunits was studied using
immunohistochemistry, immunoblotting and flow cytometry. Although
expression of the B1 subunit was rare in mesothelial cells, this was present in
54% of peritoneal effusions and 27% of pleural effusions. av expression in
peritoneal effusions was 61%. Based on these results, a role was suggested for
the avBl-integrin fibronectin receptor in mediating carcinoma-mesothelium
binding (Davidson, Goldberg et al., 2003). Ishii et al demonstrated in their
study with murine invasion models and humangastric cancer samples role for
integrin «684 as a biological marker for both the prediction of recurrence of
peritoneal dissemination and the outcome ofpatients with gastric cancer. Integrin
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a6B4 suppressed peritoneal dissemination by inducing apoptosis in metastatic
models. The loss of integrin «684 expression in gastric cancer accelerated
peritoneal dissemination (Ishii, Ochiai et al., 2000).
3.6.2.4 CD44
CD44 comprises a family of heterogeneous integral membrane
proteoglycans derived from a single gene. This gene is composedof20 exons, 10
of which are variably expressed due to alternative splicing. CD44 functions
primarily in the immune system. CD44 andintegrins are thought to be involved
in the peritoneal dissemination of cancer cells and in the adhesion of cancercells
to extracellular matrix components such as collagen, laminin, fibronectin and
hyaluronic acid. Nakashio et al (Nakashio, Narita et al., 1997a) studied the role
of adhesion molecules using monolayer models of mesothelial cells and gastric
cancercell lines. They found that strong expression of CD44H and B1 and weak
expression of a5 integrin in cancer cells are necessary for an early development
of peritoneal metastasis. The same authors also found that the binding activity
and invasion of NUGC-4 gastric cancer cells into mesothelial cells appeared
increased by pre-incubating mesothelial cells with TGF-B1.
3.6.3 CYTOKINES AND CHEMOKINES
Cytokines are polypeptide products of many cell types that are able to
modulate the action of other cell types. Chemokines are a group of heparin-
binding cytokines that act as powerful chemo-attractants for leukocytes, and are
well knownfor their role in acute and chronic inflammatory reaction (Yoshie,
Imai etal., 2001). In recent years there has been a growinginterestin the role of
these molecules in neoplasia and metastasis. There is increasing evidence that
certain aspects of tumour growth are related to persistent and unresolving
inflammation (Szlosarek, Charles et al., 2006). Particularly chronic
inflammation, with the persistence of an inflammatory trigger provided by pro-
inflammatory cytokines is partly responsible for the process of carcinogenesis.
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An example is the process of chronic gastric infection with Helicobacter pylori,
where there is strong association with the presence of Interleukin 18, and
polymorphisms in the gene expressing this cytokine are associated with gastric
cancer (Dinarello, 2006). Likewise, TNF-a whichis upregulated at an early stage
after infection and polymorphicvariants of IL-10, an anti-inflammatory cytokine
that inhibits cell mediated immune responses, have been associated with an
increased risk of gastric cancer (El-Omar, Rabkin et al., 2003) . Several
cytokines of the growth factor family have been identified in gastric cancer
according to histopathological type. For instance epidermal growth factor,
tumour growth factor a and basic fibroblast growth factor are usually
overexpressed in the intestinal type, whereas tumour growth factor 8 and basic
fibroblast growth factor are overexpressedin the diffuse type (Tahara, 2004).
Although the precise involvement of cytokines and chemokines in
peritoneal metastasis is still poorly understood, a few publications have provided
someinsight. It is of particular interest that many of these molecules seem to
inhibit on cell-cell adhesion leading into increased invasion in the peritoneum.
Interleukin 2, a mediator for activation of immune cells, has been
reported to have antitumoureffect, presumably by T cell activation, described in
some tumour models (Cayeux,Richter et al., 1997). Interleukin 6, whichtriggers
antibody secretion and maturation of B lymphocytes, stimulates tumourcell
growth in most cases, such as gastric carcinoma (Schneider, Hoeflich et al.,
2000). Ikeguchi et al. studied the expression of a number of cytokines in
peritoneal washing from patients with gastric cancer. They found lowerlevels of
Interleukin 2 (IL-2) and higher levels of Interleukin 6 (IL-6) in patients with
peritoneal seeding, while levels of Interleukin 12 (IL-12) and Tumour Growth
Factor 8 did not differ from those seen in controls (Ikeguchi, Matsumoto etal.,
2004).
IL-12 has also been linked to carcinogenesis, although its role is less
understood. During inflammation, antigen presenting cells, such as macrophages
secrete IL-12, which activates natural killer cells and T cells to produce of
interferon y and increasing NK and cell cytotoxicity and proliferation (Gately,
Renzetti et al., 1998). Murakami et al studied IL-12 levels in humangastric
cancer (127 patients and 35 controls). They concluded that whilst IL-12 levels
were higher in gastric cancer patients compared to controls, patients with
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advanced disease and indeed peritoneal seeding had lower IL-12 serum levels
and IL-2 receptor levels than patients with early gastric cancer. The same author
already reported 10 years earlier that IL-2 receptor levels were higher overall in
gastric cancer, but not significantly different in the presence of liver or peritoneal
metastasis. However the reasons for this difference were unclear (Murakami,
Okuboetal., 2004;Murakami, Satomiet al., 1994)
Yasumoto et al reported that the chemokine receptor CXCR4 was very
highly expressed in metastatic gastric cancer cell lines compared to primary
gastric cancer cells. They were able to demonstrate suppression of peritoneal
metastasis in a peritoneal model using a CXCR4receptor antagonist (Yasumoto,
Koizumiet al., 2006).
Alkhamesi et al reported that the expression of ICAM-1 in mesothelial
cells was increased in the presence of the pro-inflammatory cytokine Tumour
Necrosis Factor Alpha (TNF-a). Increasing evidence suggests that chronic TNF-
a production regulates many processes such as angiogenesis, cell replication,
apoptosis and tumour progression at cellular level (Szlosarek, Charles et al.,
2006). In the peritoneum, this change in ICAM-1 concentration enhanced the
ability of tumour cells to adhere and invade peritoneum in mice(Alkhamesi,
Ziprin et al., 2005). Mochizuki et al also reported similar findings regarding the
role of TNF-a. Mesothelial cells suffered morphological changes, including
decrease in actin stress fibre levels and intercellular gap formation. Loss of
HPMC cell-cell adhesion led to increased tumour-mesothelial cell adhesion
(Mochizuki, Nakanishi et al., 2004). Different results had previously been
published by Van Rosenet al (van Rossen, Hoflandet al., 2001) who performed
similar experiments with a colonic cancer cell line in mesothelial rat cells. They
found that Interferon-gamma (IFN-gamma), TNF-a, IL-6, and insulin-like
growth factor (IGF-I) pre-incubation of a monolayer of mesothelial cells had no
effect on tumour cell adhesion. These differences may illustrate important
sources of variability including possible differences in response of different
tumours (gastric versus colonic), organism (human versus rat) and experimental
model systems (mice in vivo versus mesothelial cell in vitro monolayer).
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3.6.4 ANGIOGENESIS AND GROWTH FACTORS
The role of growth factors in the development of peritoneal metastasis
has been reported in numerous publications. However, the specific role of
angiogenesis in peritoneal metastasis is a poorly understood area. While
neovascularisation may be necessary for the survival of newly formedperitoneal
deposits, further research is needed to understandall the factors involved in the
process.
The most well known angiogenic factor to date is vascular endothelial
growth factor (VEGF). VEGF, also called vascular permeability factor, is a
potent mediator of normal vessel permeability and has an endothelial cell mitotic
potential (Glass, Harper et al., 2006). Physiologically, VEGF expression is
regulated by exogenousstimuli, such as tissue hypoxia (Sooriakumaran & Kaba,
2005). VEGF maybeexpressed in tumourcells; expression may also be induced
by oncogene products. VEGF inhibition causes immature blood vessels to
regress, without disturbing normal mature blood vessels (Fang, Zhou et al.,
2007). High levels of VEGF increases vascular permeability leading to high
interstitial pressure and uneven delivery of nutrients, oxygen and even
therapeutic drugs into the tissue (Rasila, Burgeret al., 2005). The important role
of angiogenesis in the developmentof peritoneal metastasis from gastric cancer
has been further studied by Aoyagi et al (Aoyagi, Kouhuji et al., 2005). They
found that not only a higher numberof cells would show higher levels of VEGF
by immunohistochemistry when the tumour had reached the serosal layer and
invaded the peritoneum but also the intensity was higher. Having established a
scoring system for all samples, they concluded that higher immuno-staining
scores positively correlated with peritoneal recurrence thus suggesting that
VEGEFscores were a good markerof peritoneal metastasis in patients with gastric
cancer. Sako et al reported that VEGF may be produced by HPMCinlarge
amounts whenstimulated by fibroblast growth factor 2 (FGF-2), and due to the
increased vascular permeability at local level this may provide an ideal
environment for disseminated cancer cells to grow on the peritoneum (Sako,
Kitayamaetal., 2003). Gerberet al reported that angiogenesis could be promoted
in areas of the peritoneum where hypoxia was more marked, thus stimulating
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mesothelial cells to secrete VEGF promoting angiogenesis and subsequent
metastatic survival (Gerber, Rybalko et al., 2006). Garcia Gomez et al
demonstrated that HPMC cells incubated in the peritoneal cavity of rats, they
proliferated and formed neo-vessels, and synthesised basic fibroblast growth
factor and VEGF (Garcia-Gomez, Goldsmith et al., 2005).
Tumour growth factor 81, TGF-81, has also been linked to peritoneal
metastasis. This factor was reported to stimulate the production of ECM
components associated with morphological changes in mesothelial cells (Ignotz
& Massague, 1986). Nakashio et al pre-incubated the gastric cancer cell line
NUGC-4 and HMPCwith TGF-81 and observed a marked increment of binding
activity of cancer cells to HMPCthus concluding that the growth factor promotes
peritoneal metastasis (Nakashio, Narita et al., 1997b).
Hepatocyte growth factor (HGF) a growth factor mainly produced by
fibroblasts, has also been related to peritoneal metastasis. HGF greatly enhances
cell motility and breakdown of extracellular matrix in a variety of cancer cells
leading to tumourcell spread. c-Met, the HGF receptor, which is a membrane-
spanning tyrosine kinase, is over-expressed in many kinds of cancer cells
(Zarnegar & Michalopoulos, 1995). In fact, HGF acts on cancer cells via this
receptor to promote their proliferation and on stromal cells to promote
neovascularisation. Furthermore it has been shownthat inhibition of HGF with
HGF-antagonist NK4 in a murine model effectively suppressed peritoneal
metastasis (Tanaka, Shimuraet al., 2004;Ueda, Iwahashiet al., 2004).
3.6.5 MICROARRAY STUDIES TO DATE
Hybridization based quantitation of mRNA abundance has extensively
been used in molecular biology for decades. However, Northern blots, slot blots
and other related approaches could only detect one or - with the use of stripping
and rehybridization- a few genes of interest. However, the development of
microarray technology permits the simultaneous study of the expression of a
large numberof genes in a given total RNA or mRNA sample. When the samples
tested are paired, for example treated versus untreated cells or affected versus
non-affected tissue samples changes associated with the treatment or the disease
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process can theoretically identified. One of the most extensive utilization of
DNA arrays is in cancer research, where it allows the comparison of gene
expression in primary tumours, lymph nodes and distant metastases, thereby
identifying genes that are specifically over or under-expressed at different levels
during the developmentofmetastatic lesions.
The principle of printed DNA microarrays was first developed in the
nineties at Stanford University, where short DNA fragments complementary to
hundreds of genes wereprinted on glass slides using robotic technology (Schena,
Shalon et al., 1995). The RNA extracted from tissues or cells of interest was
labelled with a fluorescent dye and hybridised to the arrays. A laser scanner read
the intensity of fluorescence at each spot present on the platform. With the aid of
computer software spot intensities were translated into a numerical value that
was proportional to the abundance of the mRNA hybridized to each particular
spot. Subsequently, changes were made tothe printing process, including the use
of single stranded gene-specific oligonucleotides, and the isolation and
amplification of mRNA from tissues of interest. This technology is used in
numerousareas of medicine and biology andparticularly in cancer research.
Since 1999, there has been an increasing use of microarrays in cancer
studies. These early investigations contributed to the discovery of new subtypes
of cancers and have shown the diagnostic and prognostic potential of this
approach. Studies on a numberofsolid tumours included prostate cancer (Bull,
Ellison et al., 2001;Dhanasekaran, Barrette et al., 2001), breast cancer
(Hedenfalk, Duggan et al., 2001), oesophageal cancer (Fukuda, Sakakuraet al.,
2004), ovarian cancer (Yoshida, Furukawa et al., 2009), colon cancer
(Witkowska, Gumprecht et al., 2010), lung cancer (Yang & Sun, 2010) and
gastric malignancies (Mimori, Fukagawaetal., 2008;Wang, Zhuet al., 2006).
Subsequently it has been possible to print thousands of gene fragments
on oneslide which allows the simultaneous study of many gene expression levels
on eachslide. Isolated mRNA from tissue of interest is amplified, labelled and
hybridised to the DNA fragments on the platform. A laser scanner reads the
intensity as fluorescence of each spot in the platform. With the aid of computer
software it is possible to collect those images containing spot intensities and
translate them into numerical data that can be further analysed. Hence it is
possible to learn expression levels of thousands of genes from each sample and
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establish comparisons amongst numerous samples which will lead to meaningful
conclusions. Microarray technology has dramatically changed the approach to
molecular biology research.
However, despite the extent of the literature on this topic, to date few
studies have specifically researched into the formation of peritoneal metastases.
The largest study on this topic is that of Galamb et al (Galamb, Sipos et
al., 2005), a comprehensive review of 12 publications in gastric cancer including
nearly 400 patients and a further 17 publications including 272 patients with
colorectal cancer. While the emphasis is on primary tumour gene expression, the
genesidentified provide sound understanding into the mechanisms of growth and
invasion. Despite differences in gene expression in gastric and colonic cancers,
some cellular processes were affected similarly. Upregulated genes related to
tumour suppression, oncogenes and apoptotic genes included v-raf 1, CAS and
semaphorin 5 for gastric cancer; v-myc and bel-2 for colorectal cancer. Both
tumours showed upregulated GRO-1, an oncogene activated by RAS, dependent
on p53, which is vital for cancer cell survival. Similarly, caspases 8 and 9 were
dowregulated in gastric cancer and caspase 10 in colorectal cancer, which
contribute to loss of apoptotic control, potentially leading to uncontrolled cell
growth. DNA topoisomerase 2a, involved in cell cycle control, was upregulated
in gastric cancer and downregulated in colorectal cancer. Cytokine genes such as
IGF-2, which stimulates insulin action and cell growth, and TGF-83, which
controls cell proliferation and differentiation, were upregulated in gastric cancer;
TGF-gene 83, and IFN induced protein were upregulated in colorectal cancer. No
cytokines were downregulated in gastric cancer and only HGF in colorectal
cancer. Several cadherins, catenins, integrins and other cell adhesion related
genes were upregulated in both gastric and colonic cancer. Proteases involved in
ECM digestion and remodelling were upregulated mostly in gastric cancer,
whereas only TIMP-3 was upregulated in colonic cancer. Although the gene
signatures for both cancers are different, it becomes apparent that both cancers
use similar mechanisms to invade. Oncogene activation, tumour suppression
gene suppression,loss of apoptotic control, necessary for controlled cell growth,
breakdown of ECMandloss of adhesion, are pathwaysto facilitate uncontrolled
cell growth and invasionin this study.
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When comparing primary tumour with metastatic deposits, Wang et al
(Wang, Zhu et al., 2006) found a small group of genes that were differentially
expressed, not only between normal mucosa and primary tumour, but also in
metastatic lymph nodes. These experiments were performed on human cDNA
arrays, and confirmed by RT-PCR and immunohistochemistry. OPCML,
previously reported as a tumour suppressor gene in ovarian cancer, had highest
level of expression in normal mucosa, lower in primary tumour and lowest in
metastatic lymph node. YES 1, a homolog virus oncogene associated with
oesophagealcancer followed a similar pattern of expression. ACK-1, involved in
tyrosine phosphorylation and transduction, was downregulated, and reported to
act as pro-oncogene,thus facilitating tumour progression. Although other genes,
involved in adhesion, ECM breakdown and cell cycle were identified in the
primary tumour, these were not present in the metastatic lymph nodes.
Chen, Lin et al studied a numberof cell cycle and apoptosis related
genes in human colonic cancer in 85 samples. (Chen, Lin et al., 2007).
Combining tissue microarrays and immunohistochemistry they found that p53,
p21 (responsible for cell cycle arrest in G1 phase), cyclin D, Blc-2 and Bax (both
apoptotic genes) over-expression, all showing correlation with histopathological
grade. Additionally, p53 expression levels correlated with clinical staging (Dukes
classification) and the presence of lymph node metastasis. Bcl-2 correlated with
histological grade and liver metastases. The authors proposed that loss ofcell
cycle and apoptotic control played a crucial role in colonic cancer progression
and altered Bcl-2 altered expression may be involved in development of distant
metastasis.
Sakakura et al (Sakakura, Hagiwara et al., 2002a) conducted a study of
various gastric cancerandperitoneal metastasis cell lines. They hypothesised that
gene expression in peritoneal metastasis was different to primary tumours thus
indicating that differences existed in the mechanisms of both processes. They
identified a possible metastatic signature involving up and downregulated genes
from gastric cancerrelated malignant ascites, compared to primary tumours. Two
apoptosis related genes Leukocyte elastase inhibitor and TGFb-induced
antiapoptotic factor were up-regulated in malignant ascites and peritoneal
metastasis. Nine genes were up-regulated which play a pivotalrole in adhesion.
These included integrin «3, S100 (a ligand of annexin IT) and CD44(aligand for
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integrins; over-expression of the latter was previously reported to be linked to
peritoneal metastasis by Nakashioet al (Nakashio, Naritaet al., 1997a). Keratins
7,8,14 were also over-expressed. However the adhesion related gene integrin 34
was down-regulated. Only two apoptotic genes were downregulated: H2A
histone family memberL and Death associated protein. RAD 51 homolog C, a
gene responsible for chromosomalstability, was also downregulated. Finally,
other geneslinked to various signalling pathways (examples: Histone deacetylase
3, Acyl-Coenzyme A dehydrogenase and Chaperonin containing TCP1) were
also downregulated.
Fukui et al (Fukui, Nishimori et al., 2005), in a similar study, also
identified a series of genes differentially expressed in peritoneal metastasis.
Peritoneal metastatic cancer cell lines were established from a previous gastric
cancer cell line (AZ521) grown in the abdominal cavities of nude mice. Gene
expression patterns were then compared betweenthe peritoneal metastatic versus
primary tumourcell lines. A numberof up-regulated genes were identified which
were involved in regulation of cell cycle, cell growth, DNAtranscription. These
included Mitogen induced nuclear orphan receptor, which is involved in
regulation of transcription, protein tyrosine phosphatase, involved in cell cycle
and EGRalpha,a transcription factor. Downregulated genes included IGFBP 7
(cell growth), PISSLRE (oncogenesis, cell cycle), human chorionic
gonadotrophin (8-HCG) 8 subunit (apoptosis, signal transduction) and RNA
polymerase II homolog (transcription) The cell adhesion receptor Integrin alpha
E precursor wasalso down-regulated.
Yanagihara et al (Yanagihara, Takigahira et al., 2005) conducted similar
experiments, injecting peritoneal metastatic cell lines into the peritoneal cavities
of mice. Once ascites and peritoneal deposits developed, mice were sacrificed
and gene expression patterns in the recovered tissue were analysed further. Up-
regulated genes included MMPI, apoptotic genes galectin-1 and BCL-2;
cathepsin-L, all of which are well associated with invasive tumours, and plasma
protein activated by p53 gene, which controls cell cycle. MMPI plays a pivotal
role in ECM proteolysis and its association with invasion and metastasis has
been previously documented (Inoue, Yashiro et al., 1999). Cathepsin L is a
cystein protease of the papain family and its role in ECM proteolysis has been
documented, particularly in melanoma (Yang & Cox, 2007). Down-regulated
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genes included Thrombospondins 1 and 4, CD 44 (cell adhesion, signal
transduction, calcium ion binding) and cyclin (cell cycle). In normal tissues,
thrombospondins are implicated in cell to cell adhesion, cytoskeleton
organisation and cell motility (loachim, Michael et al., 2006). CD44, a cell
membrane proteoglycan, known to be involved in cell adhesion of invading
cancer cells, was also reported to be relevant to the development of peritoneal
metastasis (Nakashio, Naritaet al., 1997a).
Mimori et al studied MTI-MMP (membrane type matrix
metalloproteinase, previously recognised as a key molecule in primary tumour
invasion) in metastatic gastric cancer using microarray technology. Tissue
samples from six cases of recurrent gastric cancer after surgery were compared to
3 non recurrent gastric cancer controls. They also studied blood and bone
marrow samples of 810 patients with gastric cancer (629 undifferentiated and
181 differentiated tumours, using blood samples taken in the anaesthetic room
before surgery. 26 of these patients had peritoneal metastasis. They found higher
levels of circulating blood and bone marrow MTI1-MMPin patients with
peritoneal metastasis, compared to controls. Particularly, significant correlation
was found between high levels of MT1-MMP-1 in both circulating blood and
bone marrow and the presence of peritoneal metastases. When multivariate
analysis was performed using a logistic regression model, they found that blood
levels of MTI1-MMP were associated with a higher potential for peritoneal
metastasis. Likewise when levels were higher in bone marrow,these correlated
with higher potential for haematogenous metastasis. (Mimori, Fukagawaetal.,
2008).
Varghese et al carried out gene expression profile of metastasis to the
liver and peritoneum from patients with lower gastrointestinal malignancy.
Although peritoneal dissemination is less common than liver metastasis, its
presence has a detrimental effect on the management and prognosis of these
patients. The study was performed on 20 patients with colorectal cancer, 6 of
who had peritoneal metastasis with no hepatic involvement. Genes that were
differentially upregulated in the presence of peritoneal metastasis, included
CD14, V-CAM, IGF-1 and Thrombospondin 1, all of which are angiogenic
factors. Also upregulated were TIMP-1 (a tissue metalloproteinase inhibitor with
well recognised role in metastasis formation) and TGF-8 and EGR-1 (early
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growth response factor) both of which are involvedin cell cycle control. This is
the first publication that has also identified angiogenesis related genes which
appeared to be overexpressed in peritoneal metastasis from colorectal cancer.
Finally adhesion molecules such as chondroitin sulphate proteoglycan 2, TGF- }
and various cadherins and integrins were also involved. These findings
corroborate that functions already described above play a very important role in
the developmentof peritoneal metastasis (Varghese, Burnesset al., 2007).
All the above studies aimed to explain the possible molecular pathways
involved in cancer cell growth metastasis formation (Figure 3). However, this
quick overview highlights the deficiencies of these investigations. Some of the
studies were conducted directly on tissue samples obtained during surgery; other
used established cell lines while alternatives included the study of the process of
peritoneal metastasis formation in very artificial animal models. In addition, the
use of the range of different array platforms and non-standardised sample
handling protocols make the comparisons between these studies difficult.
Nonetheless, when gene functions are compared amongst the studies, it may be
concluded that certain molecular pathways share some similarities across the
studies. Changes in oncogene activation, mutated tumour suppressor genes,
increased proteolysis, loss of cell to cell adhesion, abnormalcell cycle control,
inability to repair DNA damageandloss of apoptotic control were pathways seen
in multiple studies. At the same time,it is also noticeable that microarray studies
so far failed to identify the role of certain biological pathways, such as
angiogenesis in the process of peritoneal metastasis. Furthermore, comparison
between the studies published to date fails to identify a core set of genes that
appearto be essential for the formation of peritoneal metastases.
A major drawback in microarray technology is that it is not possible to
stratify steps within molecular pathway into those particular to peritoneal
metastasis and separable from those relevant to primary tumour formation.
Further research into this field is required, ideally with larger numbers of
subjects and enoughperitoneal metastatic tissue available.
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3.7 IMPORTANCE OF A SUITABLE MODEL
One major hurdle in the study of peritoneal metastasis in humans is the
nature of the clinical context. As most of the patients with peritoneal metastases
are debilitated and have very limited life expectancy, large scale or prolonged
clinical studies are usually impossible. Thus a suitable model of peritoneal
metastasis is needed, which resembles, as closely as possible the human
peritoneum,to allow further experiments on mechanisms of metastases. To date
most of the knowledge aboutperitoneal metastasis has been gained from work on
mesothelial monolayer cultures and animal models but both of these have their
limitations. Mesothelial monolayer studies typically consist of mesothelial cells
laid in a tissue culture plate; onto which cancer cells are applied. Using this
system it is possible to observe growth along the surface of the mesothelial layer,
but the depth of invasion cannot be assessed. Thusthese studies are restricted
and provide information on the initial stages of the metastatic process only. In
contrast animal models usually involve injected cancer cells from either
commercially available cell lines or modifications thereof into the peritoneal
cavity. Metastatic behaviour may be observedbysacrificing the animals after a
period of days or weeks (Nishimori, Yasoshima et al., 2000). However to
observe multiple time points requires many animals, and can provecostly.
To overcomethese problemsa more representative experimental model has
been developed which offers a reliable means of pre-animal experimental study.
The three-dimensional peritoneal model described by Jayneet al (Jayne, O'Leary
et al., 1999a) is fabricated from humanperitoneal mesothelial cells, fibroblasts
and rat tail collagen, and is a much closer representation of the human
peritoneum than the simple mesothelial monolayer.
The source of humanperitoneal mesothelial cells (HPMC) for such models
can also be problematic. HPMC have also been isolated from human serous
effusions, like peritonealascitic fluid or pleural collections. Howeverthis method
is not popular because they may also contain other cells, and such effusions are
often a sign of underlying disease (Allen, Porteret al., 1987;Jap, Mungyeretal.,
1984;Sakakura, Hagiwaraetal., 2002b;Zhang, Pettengell et al., 1999) which may
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be a confounding factor. To avoid these concerns HPMCcanalso be harvested
from peritoneum during surgery for benign disease.
However the in vitro peritoneal model of peritoneum also has some
limitations. While valuable information may be gained aboutthe early stages of
invasion of the in vitro models, these are removed from culture after a given
number of days. If models could survive weeks or months, a more thorough
study of peritoneal metastasis during later stages of the disease could be possible.
Moreover, only three cell types are present in the model: cancercells, fibroblasts
and HPMC.There are no vessels nor blood supply, no immune system, which
translates into a lack of ability to generate a systemic response to invasion, asit
would take place in humans. Therefore, some functions which take place at the
very local level, such as disruption of HPMC adhesion and proteolysis of the
extracellular matrix may be reproduced in an in vitro model, whereas the
understanding of those functions provided by a host response such as immunity,
angiogenesis, cell repair or apoptosis may belimited.
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4 AIMS AND METHODOLOGY
The studies described centred on the use of an in-vitro model system to
study the mechanisms of humanperitoneal metastases, and to define molecular
features which distinguish tumours with high propensity for peritoneal invasion.
The main hypothesis was that gene expression by invading cancercells and host
mesothelial cells in a 3D model of peritoneum would correlate with observed
microscopic invasion. The experimental aimsare outlined below:
1. To establish the 3-D model of human peritoneum as described by
Jayne et al (Jayne, O'Leary et al., 1999b)
2. To characterise the behaviour of the cancer cell lines with different
metastatic potential on this model using immunocytochemistry
3. To extract mRNA from cancercells and associated mesothelial cells
using laser capture microdissection
4. To study patterns of gene expression using amplified RNA and
cancer microarrays
5. To define gene expression changes which may be particularly
importantin the process of peritoneal invasion
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5 MATERIALS AND METHODS
5.1 TUMOURCELLLINES
All cell lines were kindly provided by S McMillan, Department of Surgery,
the Royal Liverpool Hospital NHS Trust and the University of Liverpool. Details
of eachcell line are specified in table 7.
 HT 29 SW480 TMK KATO
Species Human Human Human Human
Origin Colon Colon Stomach Metastatic,
Pleural
Histology well differentiated gradeIII-IV Undifferentiated, Signet ring
adenocarcinoma adenocarcinoma diffuse type carcinoma of
(scirrhous) the stomach
Metastatic Low Low-medium High High
Potential
Characteristics Fast growth, Fast growth, Fast growth Slow growth
Culture
requirements
adherentcells
RPMI10% FCS,
penicillin-
streptomycin and
glutamine
adherentcells
RPMI 10%
FCS,penicillin-
streptomycin
and glutamine
RPMI10% FCS,
penicillin-
streptomycin and
glutamine
RPMI20%
FCS,
penicillin-
streptomycin
and glutamine
Table 3 Fourcancercell lines were used for invasion of the 3D model. HT29 and
SW480 were colonic cancers and TMK and KATO wereprimary and metastatic
gastric cancers respectively.
4I
5.1.1 CELL CULTURE
Handling of tissue culture flasks was always performed in a laminar
airflow safety cabinet, in the tissue culture room. Medium was changed every
two to three days, according to cell requirements. Cells were checked for
confluence under a phase contrast microscope (Leica, Leica Geosystems AG
Heerbrugg, Switzerland, www.leica.com). When they reached 80% confluence
they were subcultured using 0.05% Trypsin EDTA (Gibco, Gibco®, Invitrogen,
Paisley, UK, www.invitrogen.com) and resuspendedin fresh medium.
5.1.2 MYCOPLASMA DETECTION
All cell lines, HT29, TMKI, Kato III and SW480 wereroutinely tested for
mycoplasma before every new batch of invasive peritoneal models was made
(Appendix 8.1.1). If mycoplasma infection was detected, cells were excluded
from any further experiments.
The PCR Mycoplasma Detection Set (Takara Bio Inc.) was used. This
primer set allowed the detection of the following mycoplasma species (M
fermentans, M hiorhinis, M arginini, M orale, M salivarium, M hominis, M
pulmonis, M arthritidis, M neurolyticum, M hyopneumoniae, M capricolum) and
Ureaplasmaurealyticum.
The supernatant from cells cultured for 4 days after subculture without
antibiotic was used as a sample. The following reaction mixture was prepared for
the first PCR:
H20 70u
10x PCR Buffer 10ul
dNTP mixture Sul
MCGpF1primer 1ul
MCGpRIprimer ul
Takara Taq 0.5ul
10ul of sample were added to the above reaction mixture to make 100yl
of total volume. 101 of water were added to the negative control and 10ul of
Control Template (1ng/l) to the positive control. All microtubes were placed in
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a gradient cycler (Eppendorf UK Itd, Histon, Cambridge, www.eppendorf.com).
The following parameters were set and PCR wasperformed:
94°C 30 seconds 1 cycle
94°C 30 seconds
55°C 2 minutes 35 cycles
72°C 1 minute
Another reaction mixture was then prepared for a second PCR by combining the
reagents as shown below:
H20 78.5ul
10x PCR Buffer 10ul
dNTP mixture Sul
MCGpF2 primer Iul
MCGpR2 primer 1ul
Takara Taq 0.5ul
1pl of each first PCR product was addedto the above reaction mixture to obtain
a final volume of 100ul. Care was taken to avoid cross contamination. All
microtubes were again placed in the gradient cycler and a second PCR was
performed. On this occasion 30 cycles rather than 35 were performed. The
amplified products were analysed by gel electrophoresis (2% agarose). The
presence and size of any DNAfragments present as bands was comparedto those
of 12 species provided by Takara Bio Inc.
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Species Pairs of Primer
Fl and R1 (bp) F2 and R2 (bp)
M hyopneumoniae 681 237
M neurolyticum 501 196
M fermentans 491 195
M pulmonis 477 189
M hiorhinis 448 211
M orale 423 179
M capricolum 415 179
M arthritidis 408 157
M salivarium 403 151
M hominis 370, 369 147, 148
M arginini 369 145
U urealyticum 482, 481 154
In order to confirm that a sample did not include any inhibition substance, a
positive control band was present in both PCR. A band of 810 bp appeared with
F1 and R1 primers, and a band of 590 bp with F2 and R2 primers.
The same protocol was used to assess the success of antibiotic treatment of
infectedcells.
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5.2 THE THREE DIMENSIONAL PERITONEAL MODEL
5.2.1 MESOTHELIAL CELL ISOLATION AND CULTURE
Humanperitoneal mesothelial cells (HPMC)andfibroblasts were isolated
from human omental tissue obtained from consenting patients undergoing
elective abdominal surgery. Ethical approval was granted by South Sefton
Research Ethics Committee. Samples of omental tissue were washed in cold PBS
and incubated in either 0.05% or 0.25% Trypsin-EDTA (Gibco, Gibco®,
Invitrogen, Paisley, UK, www.invitrogen.com) at 37°C for 10 or 20 minutes,
depending on protocol. Three different methods of HPMCisolation were used,
then assessed for HPMC growth and presence of fibroblast contamination.
Method A (n=11): incubation in 0.05% trypsin solution for 20 minutes, method
B (n=15): incubation in 0.25% trypsin for 10 minutes, method C (n=14):
incubation in 0.25% trypsin for 20 minutes. After incubation, cells released by
trypsin were collected by centrifugation of the trypsin solution for five minutesat
460 g. The cell pellet obtained was re-suspended in S5ml of complete medium
which waspreparedas follows:
500ml Dulbecco’s Modified Eagle’s Medium Ham’s F-12 (Sigma, Sigma-
Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com); 10% FCS (Sigma, Sigma-
Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com); Sml Penicillin-Streptomycin
(10,000 U/mlofpenicillin base and 10,000 pg/ml of streptomycin base utilising
penicillin G (sodium salt) and streptomycin sulfate in 0.85% saline, Gibco,
Gibco®, Invitrogen, Paisley, UK, www.invitrogen.com ) and 5ml 200mM L-
glutamine (Gibco, Gibco®,Invitrogen, Paisley, UK, www.invitrogen.com ); 5ml
Insulin-Transferrin (5Oug Insulin + 5Oug transferrin in 100ml of unprepared
medium in water bath andstirred until dissolved). Insulin was prepared from
Human Actrapid (Insulin concentration: 3.5mg/ml, Novo Nordisk A/S,
Bagsvaerd, Denmark, www.novonordisk.com). Transferrin was available from
Gibco, (Transferrin concentration: 10mg/ml, Gibco®, Invitrogen, Paisley, UK,
www.invitrogen.com); 50 ul of hydrocortisone (100mg hydrocortisone in 0.5ml
Ethanol 100% and 0.5ml of water, Solu-Cortef®, Pharmacia Corporation
Kalamazoo, Michigan 49001, USA).
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After centrifugation at 460 g for five minutes and re-suspension in fresh
complete medium,cells were transferred into a 0.2% gelatine (10 mg gelatine in
5ml PBS, BDH Chemicals Ltd, Dorset, UK) coated T25 tissue culture flask
(Greiner, Greiner Bio-One Ltd, Stonehouse, UK www.greinerbioone.com).
Every 48 hours the medium was changed. As soon as the mesothelial cells
achieved full confluence, they were split using 0.05% Trypsin-EDTA and
transferred into a 0.2% gelatine coated T75 flask.
5.2.2 FIBROBLAST ISOLATION AND CULTURE
Cell suspensions were prepared from operative samples as above.
Howeverincubation lasted 45 minutes at 60rpm in a rotating incubator and 37°C.
Medium usedfor fibroblast culture consisted of Dulbecco’s F-12 Ham medium
(Sigma, Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com) containing
10% FCS (Sigma, Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com), Sml
penicillin-streptomycin and 5ml of glutamine (Gibco, Gibco®, Invitrogen,
Paisley, UK, www.invitrogen.com ). Routine use of gelatine was not necessary
for fibroblast culture. Medium was changed every 2 to 3 days. 0.05% Trypsin
(Gibco, Gibco®, Invitrogen, Paisley, UK, www.invitrogen.com) was used to
split confluent cells as above.
5.2.3 COLLAGEN PREPARATION
Freshly removed rat tails were washed in 70% Ethanol at room
temperature for two hours. An incision was made through the length oftail with
a sterile scalpel andits skin was stripped, thus exposing four tendons. These were
also stripped, thoroughly minced in a Petri dish and transferred into a Falcon
tube (BD Biosciences, Oxford, UK, www.bdbeurope.com) containing 50ml of
17mM acetic acid (Fisher Chemicals Ltd. UK, www.fisherchemicals.co.uk).
They werestirred mechanically for 48 hours at 4°C using a R100 Rotatest shaker
(Luckham Ltd UK). Undissolved tendon was removed by centrifugation at
30000g and 4°C for 60 minutes (Beckman Ultraclear™ Centrifuge tubes,
Beckman Coulter™ Allegra 64 Centrifuge, Beckman-Coulter, High Wycombe,
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UK, www.beckmancoulter.com). Soluble collagen was precipitated by adding
0.1M NaOH (Sigma, Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com),
until pH 7. The solution wasstirred for further 90 minutes at 4°C. Precipitated
collagen was collected by centrifugation (10000g 20min 4°). Type I collagen
pellets were redissolved in sterile 17mM acetic acid bystirring at 4°C for 48
hours. The total protein content of the collagen solution was assessed at the
Department of Biochemistry, University Hospital Aintree and adjusted to be
within the range 3.5-5mg/ml.
5.2.4 FABRICATION OF THE 3D MODEL
The 3-D model was constructed as originally described by Jayne et al
(Jayne, O'Leary et al., 1999b). Peritoneal fibroblasts were suspended in Hams’s
F-12 (Sigma, Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com),at 5x10°
cells/ml and one part mixed with three parts of2xDMEM (Sigma, Sigma-Aldrich
Ltd, Dorset, UK, www.sigmaaldrich.com), one part 0.1M NaOH, one part FCS
(Sigma, Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com), and three
parts rat-tail type I collagen. 1.2ml of the above mixture was pipetted into
individual wells of a 12-well tissue culture plate and incubated at 37°C for 30
min to facilitate gel formation.
2.5ml of complete medium waspipetted into each well. The gels were incubated
for 24 hours. Thereafter they were detached from their culture wells using a
sterile 12-gauge hypodermic needle. The floating gels were cultured for another
six days to allow contraction to dense collagen matrices. The upper surfaces of
the matrices were seeded with mesothelial cells (5x10° cells in 201 Ham’s,
concentration 2.5x10° cells/ml) and allowed to attach by incubation at 37°C and
5% CO, for 30 minutes. Complete medium was added. The matrices were
cultured for a further five days to allow mesothelial cells to attain confluence. At
this point, complete medium wassubstituted for Hams’s F-12 1% FCS (Sigma,
Sigma-Aldrich Ltd, Dorset, UK, www.sigmaaldrich.com), and the models were
incubated for a further 48 hours to encourage mesothelial cell quiescence and
stimulate the resting state of the in vivo peritoneum prior to further studies.
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5.2.5 PERITONEAL MODEL INVASION
HT29, SW480, TMK and KATOIII cells were used in invasion assays.
All cancer cells were removed from their tissue culture flasks with 0.05%
Trypsin (Gibco, Gibco®, Invitrogen, Paisley, UK, www.invitrogen.com) and re-
suspended in RPMI medium. 20u1 of RPMI (Gibco, Gibco®,Invitrogen,Paisley,
UK, www.invitrogen.com) containing cancer cells at different concentrations,
measured in a haemocytometer, were gently placed on the peritoneal surface
after removing complete medium from their wells. Tissue culture plates were
immediately incubated at 37°C and 5% CO, for 30 minutes. 2.5ml of complete
medium waspipetted into each well thereafter. Medium wasreplaced every 48
hours. Pellets were snap frozen in liquid nitrogen after seven days incubation
period.
Becausethe original intention was to study the effects of seeding with
three different concentrations of cancercells (10%, 10°, 10° cells/ml) with four
different cell lines, a total of 50 individual models of were created. Two models
were made for each concentration and cell type. The 24 models were made in
duplicate. Furthermore two models of normal, un-invaded peritoneum were
made.
5.3 LIGHT MICROSCOPY CHARACTERISATION
5.3.1 HAEMATOXYLIN AND EOSIN
Paraffin sections were de-waxed twice for five minutes in xylene,
dehydrated in absolute alcohol (740P) for one minute and washed in water. They
were stained in Gill’s haematoxylin for four minutes, rinsed in water and
differentiated in 1% acid alcohol until the background became clear and nuclei
remainedintense blue. Slides were placed in warm water and then stained in 1%
eosin for four minutes. These were rinsed very briefly in water, dehydrated in
alcohol (740P) and cleared in xylene. Finally all slides were mounted in DPX
mountant medium (All reagents and materials were provided by the
Neuropathology Laboratory, The Walton Hospital for Neurology and
Neurosurgery, NHSTrust).
5.3.2 IMMUNOCYTOCHEMISTRY
The following antibodies were kindly provided by the Department of
Neuropathology as above: Cytokeratins 5, 8, 18 (Cam complex), Vimentin,
Factor VIII, CEA, CAM 5.2, EMA and CK20. Epithelial antibody Ber EP4,
ICAM, VCAM, PECAM,fibronectin and laminin were purchased from Dako
(Dako UK Ltd, Ely, www.dako.co.uk) collagens HII and IV from Chemicon
(Chemicon Europe Ltd, Hampshire, UK, www.chemicon.com). Characteristics
of the antibodies are summarised inthe table below.
Positive control tests were performed on appendix, bowel and uterus for
epithelial antibodies and adhesion molecules. Muscle wasusedtotest collagens,
fibronectin and laminin. All controls satisfactorily confirmedstaining efficiency.
A negative control using distilled water instead of antibody didnotstainatall.
Paraffin sections were de-waxed and dehydrated as above. Endogenous
peroxidase activity was blocked by placing the slides in 10% hydrogen peroxide
in absolute alcohol 740P for 15 minutes. They were then rinsed in running water
and placed in TRIS buffer (pH 7.4). The slides were placed in a solution of
1200ml of water, 120ml of 0.1M citrate buffer (pH 6) and boiled for ten minutes,
cooled immediately in cold water and washedin water thereafter. This process
was performed whenheat antigen retrieval was required, thus facilitating antigen
to antibody binding. 80ul of the primary antibody (dilution according to
manufacturer’s recommendations) were placed on the slides and incubation
followed for 30 minutes at 37°C. After washing in TRIS buffer, 80u] of the
secondary antibody wereplaced and incubation continued for another 30 minutes
at 37°C. Again the slides were washed in TRIS buffer. 80u1 of the ABC (Avidin-
Biotin) complex (Vector laboratories, Peterborough, www.vectorlabs.com) was
added on the slides. While these were incubated for 30 minutes at 37°C, liquid
DAB (Diaminobenzidine) was prepared: briefly two drops of buffer stock
(Vector laboratories, Peterborough, www.vectorlabs.com ) were added to 5 ml of
distilled water and mixed well. Four drops of DAB stock solution (Vector
laboratories, Peterborough, www.vectorlabs.com ) and 2 drops of hydrogen
peroxide were added and mixed thoroughly. The solution was used immediately.
80ul were placed onthe slides and left for 10 minutes. After washing off excess
reagentslides were counterstained with Gills Haematoxylin for 1 minute.
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Characteristics of each antibody, including, type, target cell
concentration, optimal dilution and sample preparation required are summarised
in the table below.
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5.4 LASER CAPTURE MICRODISSECTION
5.4.1 PREPARATION OF THE MODELS
Peritoneal models were removed from their 12 well tissue culture plates
and immediately frozen in liquid nitrogen to avoid RNA degradation. Frozen
samples were brought from liquid nitrogen to the cryostat (Jung CM3000Leica)
at a temperature of -20°C. Tissue was embedded in Cryoblock TBS Tissue
embedded Matrix for cryotomy. 5um tissue sections were cut with the cryotome.
Sections were stained with Haematoxylin/eosin and viewed in a phase contrast
microscope. If satisfactory peritoneal invasion by cancer cells was visualised
then further sections were cut. These were placed onslides pre-treated at 200°C
for 4 hours to destroy RNases. Each slide wasplaced in a Falcon tube and frozen
at -80°C.
5.4.2 HAEMATOXYLIN AND EOSIN STAIN OF LCM SAMPLES
All staining dishes were thoroughly cleaned, rinsed in DEPC water,
autoclaved and dried in a hot drying cabinet before use. Frozen slides were kept
for 2 minutes in a Coplin jar containing 95% Ethanol at -20°C. They were
washed in DEPC water for 30 seconds,stained in filtered Harris’s Haematoxylin
for one second, rinsed in DEPC water for one second, and placed in Scott’s
DEPCwater (1g Sodium Bicarbonate and 40g Magnesium Sulphate in 500ml of
water). The tissue was then dehydrated in 70% ethanol for 30 seconds followed
by 95% ethanol for 30 seconds. Thereafter it was stained with eosin (1% eosin in
95% ethanol) for five seconds. Finally the tissue was washed twice in 95%
ethanol for 30 seconds and dehydrated twice in 100% ethanol for 30 seconds and
twice in xylene for five minutes. The slides were then air dried for five minutes
or until xylene evaporated completely and then placed in the oven at 37°C to
keep tissues dry.
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5.4.3 LASER CAPTURE PROCEDURE
The laser capture microscope (Pixcell, Arcturus, Molecular Devices Ltd,
Berkshire, www.arctur.com) wasset as follows: sample thickness 5m,laser spot
size 7.5m, pulse power 69uW,pulse width lmsand threshold voltage 220 mV.
A cap (Capsure, LCM Caps Arcturus, Molecular Devices Ltd, Berkshire,
www.arctur.com) was placed on the slide and vacuum was applied. The laser
beam wasselectively aimedat those cells of interest. The cap was released from
the slide and rubbed against a cap pad (LCM CapsArcturus, Molecular Devices
Ltd, Berkshire, www.arctur.com) to remove unwantedtissue.
5.4.4 CELL LYSIS
Caps containing the tissue of interest were tightly placed on a 0.5ml
microtube containing 50ul of lysis buffer XB (Picopure RNA extraction Kit,
Arcturus, Molecular Devices Ltd, Berkshire, www.arctur.com). The microtubes
were incubated upside downat 42°C for 30 minutes, thus allowing the buffer in
contact with the cap surface. Thereafter the microtubes were centrifuged at 6000
g for one minuteand keptat -80°C. The product was ready for RNA extraction.
5.4.5 RNA EXTRACTION AND ISOLATION
RNAwasextracted from the LCM capsusing the Picopure RNA isolation
kit (Picopure™ RNAIsolation Kit, Arcturus, Molecular Devices Ltd, Berkshire,
www.arctur.com ). 50ul of Extraction Buffer (XB) were pipetted into a 0.5ml
microcentrifuge tube. A Capsure Macro LCM cap was inserted onto the
microcentrifuge tube which was then inverted, hence allowing all Extraction
Buffer to cover the Capsure Macro LCM Cap.Gentle tapping helped the process.
The assembly was incubated for 30 minutes at 42° and centrifuged at 800g for 2
minutes. After centrifugation, the microcentrifuge tube containedthe cell extract,
necessary to complete the protocol. The Capsure Macro LCM Cap wasremoved.
At this stage we could proceed with the RNAisolation protocol or freeze the cell
extract at -80°C.
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RNA Purification columns were pre-conditioned as follows: 250ul of
Conditioning Buffer were pipetted onto the purification columnfilter membrane.
The column was incubated for five minutes at room temperature and then
centrifuged at 16000xg for one minute.
50ul of 70% Ethanol (EtOH) were pipetted into the cell extract above and
mixed well. The mixture was pipetted into the preconditioned purification
column. The combined volumewasapproximately 100ul. Centrifugation for two
minutes at 100g followed by 30 seconds at 16000g to remove flow-through
followed. This process binds the RNA to the column. 100u1 of Wash Buffer
(W1) werepipetted into the purification column and this was centrifuged for one
minute at 8000g. A second wash and centrifugation was performed using Wash
Buffer (W2). A third wash was performed by pipetting 100u1 of W2 into the
purification column followed by centrifugation at 16000xg. If any residual W2
was left a further cycle at 16000xg for one minute followed. Finally the
purification column wastransferred to a new 0.5ml microcentrifuge tube. 30pl of
Elution Buffer was pipetted directly onto the membrane of the purification
column. The purification column was incubated for one minute at room
temperature and centrifuged for one minute at 1000xg to distribute EB in the
column and then one minute at 16000g to elute RNA. The RNA was now ready
for SMART/T7 amplification. Alternatively it could be stored at minus 80°C.
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5.5 LCM RNA AMPLIFICATION
Two rounds of amplification were necessary to obtain sufficient
representative amounts of mRNA. At the time of these experiments, the
recommended minimum amountby the slide manufacturers, MWG, was 5g per
reaction. The rational for two rounds of amplification was that insufficient
amounts ofstarting total RNA from laser captured cells would not yield enough
amplified RNA from one round only. LCM samples are well known to produce
small quantities of total RNA, and different methods of amplification have
successfully obtained sufficient amplified RNA (Luzzi, Mahadevappaet al.,
2003). In fact successful amplification from as little as one cell has been reported
(Kamme,Zhuet al., 2004).
The first round (Fig 4a) was based on a single-stranded linear
amplification protocol developed and validated by D Stirewalt et al (Stirewalt,
Pogosova-Agadjanyanetal., 2004). This switch primer protocol was a modified
version of BD SMART™ PCR cDNA (BD Biosciences, Oxford, UK,
www.bdbeurope.com). BD SMART™ technology is based on template
switching technique (switching mechanism at the 5’ end of the RNAtranscript)
thus resulting in a full length single-strand cDNA containing the complete 5’ end
of the mRNA. The usual SMART PCR protocol simultaneously amplifies
transcripts from both ends; however this technique amplifies only from the 5’
end producing large amounts of first strand cDNA. Therefore this protocol
combines the reproducibility of single-stranded linear amplification and the
amplification robustness of the PCR.
The second round (Fig 4) was performed following the protocol from
Eberwine et al. available as Amino Allyl MessageAmp™ II aRNA kit from
Ambion (Applied Biosystems, Warrington, UK, www.ambion.com).
During the first round, as shown in figure 5, total RNA, BD SMART
oligonucleotide and oligo T7 (dt) primer, (Invitrogen, Paisley, UK,
www.invitrogen.com) were used toinitiate first strand cDNA synthesis. Oligo T7
(dt) annealed to the mRNA poly A tail. When the BD Powerscript Reverse
Transcriptase reached the end of the mRNA, the enzyme’s terminal transferase
activity added a few nucleotides, primarily deoxycytidine to the 3’ end of the
cDNA. The BD SMARToligonucleotide, containing an oligo (G) sequenceatits
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3’ end, base-paired with the deoxycytidine stretch, thus creating an extended
template. The reverse transcriptase then switched templates and continued
replicating to the end of the SMARToligonucleotide. The resulting full length
single stranded cDNA contained 5’ end sequences that were complementary to
the BD SMART oligonucleotide. 5’ PCR primer II A annealed to this
complementary sequence and 50x Advantage DNA polymerase enzyme
synthesised sense strand cDNA. DET7Fprimerfilled in the above sense strands
with the complementary antisense strands in a separate reaction, thus creating
double stranded cDNA.
RNAwascreated by in vitro transcription, using the T7 amplification protocol
(MEGAscript™, Ambion, (Applied Biosystems, Warrington, UK,
www.ambion.com). The cDNA contained the T7 recognition sequence that was
used as the Oligo T7 (dt) RNA polymerase promotersite for in vitro transcription
(minimal sequence requirements TAATACCGACTCACTATAGGGAGA). The
first base incorporated during transcription was G (in bold, sequence above). The
resulting transcription from this promoter wouldresult in antisense RNA.
The second round of amplification, shown in figure 4b, was similar to the
first but the reagents and enzymes were different and switching template
technique was not used in this step; however the principle of single linear
amplification still applied. Instead random primers would anneal to the initial
aRNAin reverse transcription reaction. The resulting first strand cDNA was
primed to oligo T7 (dt) primer and DNA polymerase would synthesise double
stranded cDNA.Finally T7 amplification was performed as above, but with the
addition of aminoallyl dUTP for incorporation into the final amplified RNA
product to the master mix in order to obtain coupled RNA for enhanced
hybridisation.
Finally, RNAse free water was used as a negative control. Where
amplification was unsuccessful whether in quantity or quality, samples were
discarded and the procedure wasrepeated.
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5.5.1 FIRST ROUND OF AMPLIFICATION
5.5.1.1 FIRST STRAND cDNA SYNTHESIS
Precipitation of RNA from 30ul to a final volumeof 3.511 was performed
in a speed vac (Univapo 150 ECH).
Thefirst round of amplification was prepared as shown:
RNA mixture RNA (max 1g) 3.5ul
Smart oligo ul
T7 oligo dT (100ng/ul) 0.5ul
Master mix 5xfirst strand buffer 2ul
DDT(Dithiothreitol 20mM) Iul
dNTP mix 10mM Iu
Powerscript Reverse Transcriptase 1p
The RNA mixture was incubated at 70°C for two minutes, placed on ice
for one minute and incubated a further two minutes at 42°C to allow priming of
the oligo dt. Sul of the master mix were added and the final solution was
incubated at 42°C for one hour, followed by seven minutes at 72°C.
5.5.1.2 cDNA PURIFICATION
Purification was performed following the Quiaquick protocol (Qiagen,
Crawley, West Sussex, UK, www.giagen.com). Finally samples were eluted in
50ul of RNAsefree H20.
Briefly, to 10u1 of RT mix, 35yl of H2O, Sul of sodium acetate (pH 5.5)
and 250ul of binding buffer (five volumes) were added. The final solution was
added in the column. This was centrifuged at 10000g for one minute. After
discarding the flow-through the column was washed with 750ul of PE buffer
containing ethanol for one to two minutes and centrifuged at 10000g for one
minute. Further centrifugation was performed at full speed to dry the column.
The column wastransferred to a collection tube. 50u1 of RNAse free H2O were
added to the column,left at room temperature for one minute and centrifuged at
a9
10000g for one minute. The process wasrepeated with 30ul of RNAse free H20,
thus obtaining a final volume of approximately 80u1.
5.5.1.3 SECOND STRANDcDNA SYNTHESIS
H20 wasaddedto the above productto a final volume of 84pl. 16ul of
the master mix below were addedto the product:
10x Advantage PCR Buffer 101
dNTP mix 10mM 2ul
5’ PCR primer 2ul
50x Advantage polymerase mix 2ul
The 100p1 would undergo 10 cycles of SMART amplification (one minute at
95°C followed by 10 cycles of 15 seconds at 95°C, 30 seconds at 65°C and six
minutes at 68°C).
5.5.1.4 CDNA PURIFICATION
The PCRpurification Quiaquick protocol, (Qiagen, Crawley, West
Sussex, UK, www.giagen.com) wasusedas above.
5.5.1.5 COMPLETION OF SYNTHESIS OF DOUBLE STRANDED
CDNA
H2O was addedto the above product to a final volume of 84ul. 16pl of
the master mix below were addedto the product:
10x Advantage PCR Buffer 10ul
dNTP mix 10mM 2ul
DET7Fprimer 2ul
50x Advantage polymerase mix 2ul
The amplified cDNA wasdenatured at 95°C for 75 seconds , followed by primer
annealing at 60°C for 15 seconds and elongation at 68°C for ten minutes. Upon
completion the double stranded cDNA was purified again with the Quiaquick
protocol. As the product contained 100ul, 500u1 of PE binding buffer (5
volumes) and 10ul of Sodium Acetate (pH 5.5) were added instead atthe initial
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stage. The procedure would then continue as above. Theresulting final volume
was reduced (vacuumed)to 8.
5.5.1.6 T7 AMPLIFICATION
This process involved the synthesis (transcription) of RNA from the
DNA above with the enzyme T7 RNA polymerase. I used the above protocol
from Ambion (Applied Biosystems, Warrington, UK, www.ambion.com). 26u1
of the above were mixed with the cDNA.The solution wasleft at 37°C for 14
hours. Thereafter samples were purified and eluted in 100 ul of pre-heated
nuclease free water. aRNA integrity was measured by UV absorbanceagainst
50ul of nuclease free water. Quality was checked by 2% electrophoresis gel.
The protocol provided in the MegaScript kit from Ambion (Applied
Biosystems, Warrington, UK, www.ambion.com) was used. Onceall reagents
were defrosted they wereall put on ice except the buffer. The following mixture
was prepared at room temperature.
ATP 75mM 2ul
CTP 75mM 2ul
GTP 75mM 2ul
UTP 75mM 2ul
Buffer 2ul
Enzyme mix 2ul
12ul of the mixture were added to 8ul of cDNA.Thesolution was left at 37°C for
16 hours.
5.5.1.7. aRNA PURIFICATION
The clean-up protocol from RNeasy (Qiagen, Crawley, West Sussex, UK,
www.qiagen.com) was used. To the above cRNA mixture, 80u] of H2O and
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350ul of lysis buffer (RLT+Bmercaptoethanol) were added, and thoroughly
mixed. 250ul of 100% ethanol were added. The total solution was added to the
column, which wascentrifuged at 8000 g for 20 seconds. The column wasplaced
in a new collection tube. 500u1 of RPE buffer were added and centrifuged again
for 20 secondsat 8000 g. After discarding the flow-through, 5001 of RPE buffer
were added and centrifuged for 2 minutes at 8000g. Effluent was discarded and
the column wascentrifuged dry at 20000g for one minute. The column was
placed in a newcollection tube, 80u1 of H2O were added. The column wasleft at
room temperature for one minute and centrifuged at 8000g for another minute.
The total CRNA was measuredin the spectrophotometer against SOul of water.
5.5.2 SECOND ROUND OF AMPLIFICATION
5.5.2.1 FIRST STRAND cDNA SYNTHESIS
The Amino Allyl MessageAmp™ II (Ambion, Applied Biosystems,
Warrington, UK, www.ambion.com) was used. The first round of amplification
wasprepared as shown:
RNA mixture RNA (max 27g) 10
Second Roundprimers 2ul
Master mix _10xfirst strand buffer 2ul
RNaseinhibitor Iul
dNTP mix 4ul
Reversetrancriptase Tul
The RNA mixture was incubated at 70°C for 10 minutes and placed on ice briefly
before commencingreverse transcription. 81 of the master mix were added. The
final solution was incubated at 42°C for two hours. 111 of RNAse H wasaddedto
degrade the RNA,thus leaving DNAonly for secondstrand synthesis. Incubation
wasperformedat 70°C for 30 minutes.
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5.5.2.2 SECOND STRAND cDNA SYNTHESIS
5ul of oligo (dt) primer was added to the above mixture. The master mix
waspreparedas follows:
10x Advantage PCR Buffer 10ul
dNTP mix 4ul
RNAsefree water 58ul
DNA polymerase mix 2ul
74ul of master mix was added to the sample. The resulting mixture was placed
on ice at 16°C for two hours.
5.5.3 cDNA PURIFICATION
250ul of Binding Buffer were added to the sample and mixed thoroughly.
The mixture was passed through a cDNAfilter cartridge and centrifuged for one
minute at 10000g. Flow-through and the columns were washed with 500ul of
Wash Buffer for one minute at 10000g. Finally cDNA waseluted with 2x9ul of
nucleasefree water.
5.5.4 T7 AMPLIFICATION
The following mixture was prepared at room temperature. Aminoallyl
UTPwasincorporatedat this stage.
A, C, GTP 25mM 12ul
UTP 50mM 3 yl
aaUTP50mM 3ul (aminoallyl-UTP)
10X Buffer 4ul
Enzyme mix 4ul
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26ul of the above were mixed with the cDNA.Thesolution wasleft at 37°C for
14 hours.
5.5.5 aRNA PURIFICATION
Nuclease free water was added to each sampleto bring the final volumeto
100pl. 350u1 of aRNA binding buffer and 250u1 of ACS grade 100% ethanol
were added to the samples and these were loaded into aRNA filter cartridges.
Centrifugation for one minute at 10000g followed. Flow through was discarded
and 650u1 of wash buffer were applied to the cartridges. These were centrifuged
twice for one minute in order to removetraces of ethanol. Finally the aRNA was
eluted in 100pl of pre-heated nuclease free water. aRNA integrity was measured
by UV absorbanceagainst 50ul of nuclease free water. Quality was checked by
2% electrophoresisgel.
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5.6 RNA LABELLING
A numberof techniques are available which allow comparison of two or
more RNA samplesandidentification of differences in the abundanceofspecific
transcripts. Microarrays are one such technique, which enables relative amounts
of many hundreds of genes to be measured in different RNA samples
simultaneously. To do this the RNA from each sampleis differentially labelled,
usually with a fluorescent dye, prior to hybridisation to the microarray.
Fluorescent cyanine dyes Cy3 and Cy5 were chosen to label previously
amplified RNA which contained aminoallyl-UTP for enhanced labelling
efficiency ('t Hoen, de et al., 2003). Both cyanine dyes can be excited and
detected in the same slide. They also produce bright signals and have a wide
dynamic range of detection (Fig 5).
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Figure 5 Excitation and emission wavelengths for cyanine dyes Cy3 and CyS.
Source: M“WG,Milton Keynes, UK
Following synthesis of the antisense copy of the original mRNA (aRNA)
incorporating a proportion of aminoallyl-UTPresidues, fluorescent labels can be
covalently attached to the aminoallyl groups on the aRNA using N-hydroxyl
succinimidyl-ester derivative of each cyanine dye. NHS-esters react with amine
groups to form a covalent bond between cyanine dye and the amine group of the
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mRNAwhile the NHS-ester group is released along with fluorescence emission
(Fig 6).
Cy3 NHS ester 0
Excitation max = 548 nm ‘O-NEmission max = 562nm 0 on
0
CyS NHS ester 0
Excitation max = 646 nm O-N
Emission max = 664 nm 0
0
0% | 0R—NH, + | eo —— =irvR so; [SeoN RRNR :
Amine group on mRNA NHSester dye Conjugate NHSleaving
group
Figure 6 Chemical structure of cyanine dyes and labelling reaction. The above
diagram represents the chemical structure of both Cy3 and Cy5 cyanines. When
mRNAcovalently binds to the Cy NHSester, NHSester is released along with
emission of fluorescence. Source MWG,Milton Keynes, UK
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5.6.1 PROCEDURE
The labelling protocol of choice was Amino Allyl MessageAmp™
(Ambion, Applied Biosystems, Warrington, UK, www.ambion.com). Dyes were
purchased from Amersham Pharmacia Biotech (Amersham PLC,
Buckinghamshire, UK, www.amersham.com) and were compatible with the
above protocol. Briefly, 20ug of Amino Allyl aRNA were placed in a nuclease
free microtube and vacuumed dry. Cy3 and Cy5 monofunctional dyes were
suspended in 92ul of DMSO to makethe labelling reaction more efficient, and
kept in the dark for up to one hour before use. This would allow coupling of
eight samples, thus avoiding storage and potential dye degradation. 9ul of
coupling buffer and 11p1 of NHS ester dye were added to our dry samples.
Incubation in the dark for 30 minutes allowed coupling to occur. All reactions
were then quenched with 4.5ul of 4M Hydroxylamine and incubated at room
temperature for 15 minutes hence removing any unreacted dye molecules. Dye
labelled aRNA waspurified as follows: Nuclease free water was added to each
sample to bring the final volume to 100pl. 350u1 of aRNA binding buffer and
250ul of ACS grade 100% ethanol were added to the samples and these were
loaded into aRNA filter cartridges. Centrifugation for one minute at 10000g
followed. Flow through was discarded and 6501 of wash buffer were applied to
the cartridges. These were centrifuged twice for one minute in order to remove
traces of ethanol. Finally the aRNA waseluted in 100ul of pre-heated nuclease
free water. aRNA integrity and coupling efficiency were measured by UV
absorbance against TE buffer.
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Dye incorporation wascalculated using this formula from Ambion,available at
http://www.ambion.com/techlib/misc/aama_dye_calc.html:
Figure 7 Calculation of dye incorporation
#dye molecules Ay. 9010 M-! cm!= x1000 nt Axo dye extinction coefficient x 1000 
Dyeextinction coefficients:
Cy3 = 150000
Cy5 = 250000
All data recorded from spectrophotometric readingsare available in the appendix
section (Tables 19, 20). In order to continue the experiments, every sample and
its reference counterpart hadto fulfil these criteria:
e Minimum aRNAyield of 8ug
e A260/A280 ratio between 1.8 and 2.2
e Dyeincorporation between 20-50 molecules per 1000 nucleotides
Sample volumes containing equal amounts in pg of sample versus reference
labelled RNA were mixedtogether. The total volume was reduced (vacuumed)to
9ul. RNA mixture datais available in the appendix section (Tables 19, 20).
5.6.2 FRAGMENTATION
This procedure allowed aRNA to fragment into sizes between 60-200
nucleotides. This is a recommended step prior to hybridisation on
oligonucleotide printed microarrays. Hybridisation kinetics and overall signal
producedwill be enhanced. Reagents and protocol were available from Ambion.
To achieve this, equal amounts of sample versus reference set were vacuumed to
4.5ul and combined together. The resulting 91 were mixed with Ipl of
fragmentation buffer and incubated for 15 minutes at 70°C. 11 of stop solution
was added andthe samples were then incubated on ice for 2 minutes.
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5.7 MICROARRAY HYBRIDISATION AND DATA ANALYSIS
5.7.1 OVERVIEW
MWG Human Cancer Array slides were used. These contained
oligonucleotides representing 1,853 human genes associated with cancer
development and progression selected from the following public databases:
OMIM,(Online Mendelian Inheritance in Man, McKusick et al (McKusick,
2007)), NCBI, (National Institute for Biotechnology Information,
www.ncbi.nlm.nih.gov), SAGE (Serial Analysis of Gene Expression; John
Hopkins Oncology Center, Baltimore, USA) . The genes included carcinoma
(colon, breast, prostate, lung, bladder, kidney, liver, pancreas and thyroid),
melanoma, neuroblastoma, leukemia, lymphoma and sarcoma-related genes.
Thus, this selection of genes was thought to cover a wide range of potentially
relevant biological pathways: including cell cycle control, cell adhesion, angio-
genesis, signaling and immunity (Source MWG,Milton Keynes, UK).
Table 5 Characteristics ofMWG Cancer Arrayslides are summarised as follows.
Source: MWG, Milton Keynes, UK
 Minimal numberof genes: 1,853 cancer associated human genes
Information sources: NCBI(Release 123)
- 1,660 genes were referenced by NCBI's
Online Inheritance in Man (OMIN) as cancer
related.
- 167 were also identified as differentially ex-
pressed in cancer from Serial Analysis of Gene
Expression (SAGE).
 
Strand analyzed: Sense strand
Numberofslides: 1
Length of probes: 50 mer
Numberof oligonucleotides per gene: 1
Total numberof spots: 1,920
Replicated spots: 40
Arabidopsis control oligos: 27
1.8x1.8cm Spotarea:  
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A decision to use commercial pre-printed microarrays was taken late in
the project as attempts at in-house manufacture of spotted microarray slides
proved unsuccessful. At the time of this project the MWGslides provided a
good selection of relevant probes which could be analysed using the equipment
e.g. Affymetrix 428 Scanner, available in the laboratory. However the use of
commercial pre-printed slides cost considerably more than anticipated in the
original budget and limited the numberofpossible hybridisations.
5.7.2 PROCEDURE
To improve hybridisation reactions, labelled aRNA samples were
fragmented into smaller nucleotides (60-200), as described above. MWGsalt
based hybridisation buffer was pre-heated at 42°C for 10 minutes. 120ul of
heated hybridisation buffer was added to 11 ul of sample and mixed well, then
incubated for three minutes at 95°C and 3 minutes on ice. Then samples were
pipetted onto the MWG-Biotech Human Cancer Array (MWG,Milton Keynes,
UK) slides and incubated overnight at 42°C in a humid Genetix (Genetix,
Hampshire, UK) hybridisation chamber, with gentle agitation. Adhesive MWG
Gene Frames® were applied to the slides to seal the reaction within the slide.
The use of coverslips prevented problems such as bubbles on the platform, and
insufficient humidity or dust.
In addition, control oligonucleotides for non-human (Arabidopsis) genes
were provided by MWG._ These allowed checking the quality of the
hybridisation reaction and 2ul were added to the hybridisation solution along
with the buffer. However because of the small number of available slides, the
control nucleotides were finally not used.
Thereafter incubation slides were washed with the following buffers
prepared in DEPC water and warmedat 30°C,as follows:
Wash1: 2x SSC, 0.1% SDS
Wash2: lx SSC
Wash3: 0.5x SSC
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Slides were washed for five minutes in each wash buffer at room
temperature with gentle agitation on an orbital shaker. Finally the slides were
dried by centrifugation at room temperature for two minutes at 500g. The slides
were then read using an Affymetrix 428 scanner, and fluorescence was measured
at two wavelengths: 532 and 635nm corresponding to the emission frequencies
of the Cy3 and Cy5 dyesrespectively. Setting adjustments were performed using
the software available, as per manufacturers’ instructions (Jaguar 2.0):
1. Scan Area (ROI) This wasthe actual spotted area in the slide, cropped
and separated from the edgesofthe array.
Dye channels Cy™5, Cy™3, according to wavelength
Resolution 10 um
Gain 20-35 dB
Line average 2 (Note: This setting resolves low-expressed probes above
threshold)
wR
Wo
L
All the abovesettings except gain were constant throughout the readings.
Gain wasindividually adjusted for each slide to provide the best possible image
with minimum backgroundandphoto bleaching, (white spot), effect.
5.7.3. EXPERIMENTAL DESIGN
A reference design was adopted (Dobbin & Simon, 2002a) for these
studies. With a reference design, level of expression of any gene in a sample can
be related to the expression of that gene in the commonreference, as measured
on that slide. Subsequently, expression levels of a gene on different slides may
be compared using the commonreference to control for sources of variability,
amongst spots that affect both channels similarly (Dobbin & Simon, 2002b).
The reference design is a practical and popular choice for microarray studies
using two colour platforms (Kerr, Serikawaet al., 2007). Regarding the choice of
reference RNA,no consensushas been reached so far, but commercial reference
RNAis frequently used (Park, Cao et al., 2004). In this project total universal
reference RNA containing total RNA from 10 different human cell lines
71
(Stratagene Universal Human Reference RNA, La Jolla, CA, US
www.stratagene.com) was used.
The reference design approach seemed most appropriate for my studies,
given the multiple pair-wise comparisons of interest between models with
different cell types and at different seeding concentrations and incubations.
Furthermore, at least for the cancer cell studies, there was no clear candidate for
a control sample. The original intention was to study the effects of seeding with
three different concentrations of cancer cells (10°, 10°, 10° cells/ml) with four
different cell lines. Therefore, a total of 50 individual models of were created,
including 2 un-invaded models. As mentioned above, funding considerations
markedly limited the numberofslides and hybridisations that were possible, and
thus the final microarray studies completed were only a proportion of those
originally intended. Thus, hybridisations (sample versus reference) were finally
performed using RNA extracted from 3-D models seeded with the same cell
concentration (10° cells/ml).
Samples were made up of aRNA from each of the four cancercell lines
and from mesothelial cells from the same model, as well as samples of two
uninvaded models. Biological replicates contained RNA from different models,
from the same cancercell line. Technical replicates contained RNA from the
same model. Replicates for each hybridisation were performed as summarised
below in tables 6, 7.
Td
CANCER CELLS HT29 SW480 TMK KATO
 
Biological replicates 2 Z 2 2
Technicalreplicates 2:33 3;3 3;3 3;3
Total number of samples 5 6 6 6
MESOTHELIAL CELLS HMPC HT29 SW480 TMK KATO
 
Biological replicates 2 2 2 Z 2
Technical replicates 233 1;3 2;3 233 233
Total number of samples 5 4 5 5 5
Table 6-7 Replicate classification. For each sample there were two biological
replicates and these would provide one, two or three technical replicates.
Technical replicates are shown as numberofreplicates per biological sample,
separated by (;).
5.7.4 Analysis
Scanned images were analysed with Genepix Pro 6.0 software, Molecular
Devices Corporation, California, www.moleculardevices.com/logos). Using a
compatible gene identification file supplied by MWG Biotech, London,
automatic spot or feature detection was used, and data from both channels was
linked to the appropriate gene annotation information. The feature detection
options in Genepix wereselected as follows:
e Find irregular features
e Fill irregular features
e Resize features during alignment (Min diameter 25%-Max diameter 200%)
I
Microarray spot quality control was performed following the parameters
below, as per manufacturers’ instructions. Poor quality spots were flagged for
elimination from further analysis.
1. [SNR 635] >3 and [SNR 532] > 3
Signal to noise ratio (SNR) on both channels must be higher than 3, to
exclude spots with signal close to background, which would eventually result
in a high numberoffalse positive results arising from noise rather than true
signal (Seo, Bakayetal., 2004).
2. [Circularity] > 80
Defective spots are excluded. While there are deviations from a perfect
uniform circle, by defining spot circularity, very abnormal spots, pieces, or
scratches can be excluded from analysis (Jain, Tokuyasuetal., 2002).
3. [Rgn R2 (532/635)] > 0.6
Regression ratio for both wavelengths is higher than 0.6. Slope ofthe line of
best fit (chi-square or minimum-of-squares method) through the set of pixels
in a circle of diameter twice that of the feature-indicator of the current
feature).This value measures pixel uniformity across the feature (spot) and
excludes spots with highly non-uniform pixel intensities.
Further analysis was carried out with BRB-Array tools (version 3.3.0)
described by Simon et al (Simon, Lam et al., 2007). This is a free software
package from the Biometric Research Branch, Division of Cancer Treatment and
Diagnosis, National Cancer Institute, Rockville, Maryland, USA.It is free and
available online to download as application to be used with Microsoft Excel.
Once each array file had been processed by Genepix as above, including
flagging, but not normalised, these were loaded onto BRB astext files, which
contained information on gene ID, median and standard deviations for signal
intensity of each spot and its background. In addition the programmerequired a
Microsoft Excel experimental descriptor file. This contained the names of the
samples to which the files would subsequently be linked. The files were then
loaded into BRB-Array tools in class comparison mode. Data normalisation was
performed before the analysis. A submenu named “filter and subset the data”
provided the normalisation options. The programme offered two options: to
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normalise using the median over house-keeping genes or to normalise over the
entire array, using median array as reference. In this project, normalisation was
performed over the entire array. Median centring, as previously described by
Eisenet al (Eisen, Spellmanet al., 1998), allowed removal of any systematic bias
in expression between different cell-type models and facilitated comparison
across columns.
Once the data was flagged and normalised, the analysis was performed
using the class comparison approach. This allowed identification of differentially
expressed genes among samples, both biological and technical replicates. Each
biological sample was defined as named class, and within each class technical
replicates were included for analysis. Gene expression of different technical
replicates was averaged for each class. Then differences amongst classes were
analysed as mean log-ratios between the classes, relative to the variation
expected in the mean differences. The variation was computed assumingthatall
the samples were independent. The class comparison between groupsof arrays
was calculated with the F test (a generalisation of the t-test which allowed
comparisons amongst groups) separately for each gene using normalised log
ratios from the arrays. The random variance version of the F-test was used,
because the number of samples per class was small. Random variancetests take
into account information among genesof the within-class variance in log-ratios.
Subsequently the class comparison tool computed the numberof genes that were
differentially expressed among the classes at the statistical significance level
selected in the F-test menu,in this project set at p<0.001, and finally generated a
list of differentially expressed genes.
Moreover BRB array tools also provided univariate permutation tests for
the significance ofindividual genes. This test looked into which genes belonged
to what classes. For each random permutation, random variance F-test was re-
computed for each gene. This provided the proportion of random permutations
that would result in as many genessignificant at the level selected by the user as
were found in comparing the trueclass labels. In summary this approach allowed
to compare gene expression patterns within each class, which is easier than to
calculate exactly what genesare different amongstthe classes.
The false discovery rate was also calculated as an estimate of the
proportion of the genes with univariate p valuesless than or equal to the one in
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that row that represent false positives. The method of Benjamini and Hochberg
was usedfor this estimation (Hochberg & Benjamini, 1990).
The analysis strategy for this project, aimed to maximise the sensitivity of
the study and minimise the rate of false discoveries by setting the p-value at
p<0.001 with a maximum false discovery rate set at 10 genes or 10% ofthe total
of the genesidentified as differentially regulated.
5.8 REAL TIME PCR VALIDATION STUDIES
5.8.1 INTRODUCTION
Real-time PCR was used to corroborate some of the findings of the
microarray studies. Three different genes were selected: cathepsin k, caspase 8
and vimentin. They represent different pathways (ECM proteolysis, apoptosis
and cytoskeletal disruption) that could be relevant to the process of peritoneal
metastasis. Cathepsin K gene encodes for a lysosomal cystein protease, usually
found in osteoclasts (Li, Yasuda et al., 2004). The role of this collagenase in
neoplasia is well recognised, particularly in breast, lung, prostate cancer and
bone metastasis although less understood in gastrointestinal malignancy
(Brubaker, Vessella et al., 2003;Rapa, Volante et al., 2006;Rose & Siegel, 2010).
Caspase 8 is a protein involved in the extrinsic pathway of caspase
activation, necessary to trigger cell apoptosis. Disruption of apoptosis may lead
to the development of cancer (Hajra & Liu, 2004) Regarding caspase 8
expression in mesothelial cells, there is one study based on peritonitis.
Mesothelial cells were activated by TNF-a and entered apoptosis via the Fas/Fas
(CD95, TNF,caspase 8 and nerve growth factor receptor family) ligand pathway.
Chen et al concluded that mesothelial cell apoptosis during peritonitis may be
related to the resolution of peritoneal inflammation(Chen, Chiet al., 2003).
Vimentin is an important component of the cytoskeleton along with
microfilaments (actins) and microtubules (tubulins) (Source: Entrez Gene,
www.ncbi.nlm.nih.gov ). This gene was selected to assess whether destruction of
the cytoskeleton architecture in host mesothelial cells was a relevant step during
the process of invasion. The role of vimentin in peritoneal disease has been
reported in ovarian cancer and pseudomixomaperitonei, but is poorly understood
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in peritoneal metastasis (Bibi, Pranesh et al., 2006;Zhang, Pettengell et al.,
1999).
Genes were selected from validated probes available from Qiagen
(www.qiagen.com, Qiagen Ltd, West Sussex, UK): Vimentin (Hs_VIM_1_FAM
QuantiTect Gene Expression Assay (100), locus link 7431, Catalog: 241356),
Caspase 8 (HsCASP81FAM QuantiTect Gene Expression Assay (100)
Catalog: 841241136) and Cathepsin K (HsCTSK_1FAM QuantiTect Gene
Expression Assay (100), locus link 1513, Catalog 241681).
The PCR assays used (QuantiTect Multiplex PCR, www.qiagen.com,
Qiagen Ltd, West Sussex, UK) included primers and probes for the gene of
interest and a normalising gene (GAPDH). Asthe probes for both target and
GAPDHgenesweredifferentially-labelled with fluorescent dyes (FAM and JOE
respectively) both could be measured simultaneously in the same multiplex PCR
reaction. Standard curves constructed using serial dilutions of reference RNA
were used to determine the efficiency of amplification for GAPDH andtarget
gene for each combined PCR reaction. Relative quantification of gene
expression was then determined in each sample, using normalisation to GAPDH
levels, and the Pfaffl method (Pfaffl, 2001) with the least invasive cell type
(HT29)as the calibrator or baseline with which other samples were compared.
5.8.2 REVERSE TRANSCRIPTION
Amplified RNA from all samples and the reference set was reverse
transcribed using the kit from Promega (IMPROM II, Cat A#3800,
www.promega.com Promega UK Itd, Southampton, UK). Templates were
prepared as shown:
Experimental RNA (up to |pg/reaction)(1) Il
Random Primer, 0.5yg/p1 (0.5ug/reaction) 1ul
Nuclease-Free Water 3ul
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The above mixture was denatured by incubation at 70°C for five minutes,
followed by five minutes on ice. A positive control Template (1.2kb Kanamycin
Positive Control RNA)anda negative control (RNAsefree water) were included.
The master mix was prepared as follows:
Nuclease-Free Water 6.11
ImProm-II™ 5X Reaction Buffer 4.0ul
MgCl2, 25mM 2.4ul
dNTP Mix, 10mM,each dNTP(final concentration 0.5mM) 1.0u1
Recombinant RNasin® Ribonuclease Inhibitor 0.5pl
ImProm-II™ Reverse Transcriptase 1.0ul
Final Volume 15.0pl
15ul of the master mix were added to the above samples. Reverse transcription
was performed:
Annealing 2a°C 5 minutes
RT 42°C 1 hour
RTinactivation 70°C 15 minutes
Samples from the reference set previously used in microarray experiments were
serially diluted, 10 fold, to perform calibration curves. At this point samples were
frozen at -20°C or used in the next step. Spectrophotometry was not performed at
this stage due to the small amounts of DNAper sample.
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5.8.3 REAL TIME PCR
The protocol used was from QuantiTect Multiplex PCR
(www.qiagen.com, Qiagen Ltd, West Sussex, UK), which had a specifically pre-
mixed and pre-optimized Mastermix, containing HotStar Taq DNA polymerase,
dNTPs, fluorescent dye and RNAse free water. DNase I treatment prior to reverse
transcription was not used. This prevents DNA contamination of the samples;
howeverI was not familiar with its use at the time of the experiments.
The mixture wasprepared as follows:
Primer, (gene specific) lul
Probe, (antisense sequence) Iul
GAPDH(primerand probe) 2ul
RNAse free water Sul
Mastermix 10ul1
To the above 19 yl we add | wl of sample (CDNA). Hence these are 20u1
reactions. During every experiment a negative control containing no DNA was
included.
All reactions were performed in a Rotor-gene™, (Machine serial number
110159, www.corbettlifescience.com, Corbett Life Science, Sydney, Australia)
using a 72 well rotor. PCR settings were as follows:
Hold 15min at 95°C (Hot Taq activation)
Followed by 50 cyclesof:
45 secondsat 94°C, (Denaturation)
45 secondsat 56°C, (Annealing)
45 seconds at 76°C, (Extension)
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Channelsettings were set as follows:
 Channel Source Detector Gain
FAM 470 510 7
JOE 530 555 9
Table 8 Channelsettings for both FAM and JOE channels
Rotor-gene version 6 software, (www.corbettlifescience.com, Corbett Life Science,
Sydney, Australia), was used for analysis.
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RESULTS
6 DEVELOPMENT OF A 3D MODEL OF
PERITONEUM
Thein-vitro 3D model of peritoneum was the platform used to perform
invasion with various gastrointestinal cancercell lines. The interaction between
invading cancer cells and host mesothelial cells was studied to understand the
mechanisms of humanperitoneal metastases, and to identify those molecular
features which maydistinguish tumours with different propensity for peritoneal
invasion. The main hypothesis was that gene expression by invading cancer
cells and host mesothelial cells in a 3D model of peritoneum would be
associated with observed microscopic invasion.
The choice of a humanin vitro model of peritoneum was based on the
difficulties encountered when studies are to be performed in patients. Most
patients with peritoneal metastases have very limited life expectancy, thus
preventing large scale or prolongedclinical studies. Therefore, the 3D model of
peritoneum would represent the closest match to human peritoneum. It was
aimed in this project to demonstrate for the first time that such model could be
useful to research into the molecular biology of metastases.
However the in vitro peritoneal model of peritoneum also had some
limitations. Its design was technically challenging, particularly regarding the
isolation and growth of HMPC. While valuable information could be gained
about the early stages of invasion of the in vitro models, these were removed
from culture after a given number of days. The lifespan of the models was
limited. If they could survive weeks or months, a more thorough study of
peritoneal metastasis during later stages of the disease would be possible.
Moreover, only three cell types were present in the model: cancer cells,
fibroblasts and HPMC. There are no vessels nor blood supply, no immune
system, whichtranslates into a lack of ability to generate a systemic response to
invasion, as it would take place in humans. Therefore, those functions which
take place at the very local level, such as disruption of HPMC adhesion and
proteolysis of the extracellular matrix may be reproducedin an in vitro model.
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Since little is known about the molecular biology of peritoneal metastasis, this
initial approachto the steps that take place at local level may in fact be benefitial
because ofits potential simplicity compared to a model with a systemic reponse.
Howeverthe understanding of those functions provided by a host response such
as immunity, angiogenesis, cell repair or apoptosis in the 3D model of
peritoneum maybelimited or non-existent.
6.1 HPMC ISOLATION AND GROWTH
In the process of collecting omental samples from patients undergoing
laparotomy, three different methods of HPMC isolation were compared, to
establish which was superior in terms of HPMC growth success and absence of
fibroblast contamination. Figure 8A-D demonstrated successful isolation and
growth to full confluence without fibroblast contamination. Table 9 below
showedthe isolation results. No HPMC wererecovered using method A (0.05%
trypsin for 20 minutes), whereas 71% of samples using method C (0.25% trypsin
for 20 minutes), and 26% of samples using method B (0.25% trypsin for 10
minutes) yielded HPMC. Furthermore the proportion of samples yielding
HPMCwassignificantly higher for method C compared to method B (C versus
B, Fisher's exact test p=0.02). The presence of fibroblast contamination was
also more common for method B (53%) than method C (21%) although this
difference was notstatistically significant (Fisher's exact test p=0.128). HPMC
were usually discarded either after 3 passages or in the presence of fibroblast
contamination.
After optimizing the trypsin digestion conditions of the omentum
samples, HMPCandfibroblasts were isolated and cultured. The 3D model was
established from these cells and collagen. As confirmed by both light
microscopy and immunocytochemistry the models consisted of a distinct
fibroblast and collagen cove coated by HPMCs, which formed a monolayer
without showing any signs of invasive behavior. The availability of these 3D
peritoneal models made the next stage of the planned work possible. The
invasion of these structures by various cancer cells will be discussed in the
following chapter.
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 HPMC CELL ISOLATION FROM HUMAN OMENTUM
0.05% Trypsin 0.25% Trypsin
20 minutes 10 minutes
Number(Total=40) 11 15
Satisfactory growth 0 4 (26%)
Absent growth 11 (100%) 3 (21%)
Fibroblast contamination 0 8 (53%)
0.25% Trypsin
20 minutes
14
10 (71%)
1 (8%)
3 (21%)
 Table 9 HMPCisolation. Optimal results were achieved with 0.25 trypsin
digestion for 20 minutes. Neither experiment improved fibroblast contamination.
 
  aeFigure 8 HMPC isolation and growth characteristics. (A) Following
 
peritoneal digestion with trypsin, HPCM cells appeared as large
nucleated cells (solid arrow in magnified x100 inset) surrounded by
red bloodcells. (B) Culture morphology after RBC removal. (C) HPCM
cultures heavily contaminated with fibroblasts (inset magnified
x100). (D) Confluent HPMC cultures without fibroblast contamination
forming a typical mosaic pattern, as previously described (Stylianou,
Jenner et al., 1990b). Magnifications: A x40; B x100; C and D x20.
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6.2 EXTRACELLULAR MATRIX
The extracellular matrix was compound of fibroblasts and the extract
from rat tail collagen. Satisfactory fibroblast isolation only required omental
samples to be minced thoroughly and digested with trypsin as described in
materials and methods. 40 specimens of omental tissue were used. They all
yielded adequate numbersoffibroblasts for use in the 3D model. Cells grew in a
spindle shaped fashion as shownin figure 14. Gels containing rat tail collagen
and fibroblasts were incubated for 24 hours. They were analysed by light
microscopy prior to detachment from the wells. Figures 9A, B, below,
demonstrated satisfactory fibroblast growth, with a bipolar or multipolar
(stellate) morphology within the extracellular matrix made ofrat tail collagen.
Once disengaged from the tissue culture wells, fibroblasts initiated gel
contraction until a dense matrix was fully formed within 5 days. Thereafter
mesothelial cells were seeded on these collagenlattices.
Rat-tail collagen was the best choice for an in vitro extracellular matrix.It
had been used successfully by other authors, was cheap and immediately
available. The newly formed extracellular matrix allowed mesothelial cells to
grow as a monolayer, and provided a suitable matrix for fibroblast proliferation
within.
 
Figures 9A, 9B (A) Fibroblasts grow spindle-shaped to full confluence
(magnification 4x). (B) Fibroblasts (F) within the extracellular matrix (ECM) had a
bipolar or multipolar shape before contraction of the ECM (magnification 10x)
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6.3 LIGHT MICROSCOPIC CHARACTERISATION OF THE
MODEL
6.3.1 H&E
A total of 50 peritoneal models of invasion were created. Mesothelial
cells seeded onto the upper surface of the above matrices proliferated over five
days. Thereafter, a full 3D model of peritoneum was formed. 3D models were
examined by light microscopy using both Haematoxylin, Eosin and
immunocytochemistry techniques, to characterise cells and confirm findings
previously reported by Jayne et al (Jayne, O'Leary et al., 1999b). Mesothelial
cells did not invade into the matrix (Fig 10A, B). Instead they formed a confluent
monolayeroverthe extracellular matrix. Fibroblasts grew within the extracellular
matrix only. They did not grow within or above the mesothelial monolayer.
Although, no physical basal membrane was visible between mesothelium and
extracellular matrix, mesothelial cells were never seen within the extracellular
matrix, thus implying that a barrier was present, which prevented these non
cancercells from invading the models.
6.3.2 IMMUNOCYTOCHEMISTRY
Immunocytochemistry wascrucial to confirm the nature of the cell lines
involved in the 3D model. Mesothelial characteristics on the surface monolayer
were identified as follows: (positive staining for cytokeratins 8, 18, vimentin,
negative staining for von Willebrand factor and Ber EP4). Cytokeratinstipically
stained epithelial cells, von Willebrand factor stained endothelial cells and
BerEP4 stained epithelial cells of ectodermal origin. As mesothelial cells are
embriologically mesodermalin origin, they did not stain with this antibody.
Fibroblasts within the extracellular matrix were also tested (positive
staining for vimentin, negative staining for cytokeratins 8, 18, Ber EP4 and von
Willebrand factor) (Figures 11 A-D). Positive control tests were performed on
samples of human appendix, uterus. Cytokeratins 8, 18, Ber EP4 stained
epithelial cells and von Willebrand factor stained bloodvessels.
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Figures 10A, 10B Light microscopy images of H/E paraffin stained
models demonstrate the features of an in vitro 3D model of peritoneum.
(Fig A, magnification 10x) HPMC (A) grow onto the ECM surface.
Fibroblasts (F) grow within ECM. (Fig B, magnification 40x) shows a
formed mesothelial monolayer (A). HPMCdo not invade the ECM.
 
Figures 11 A-D Immunocytochemical features of HPMCandfibroblasts in a
3D model. Figure A, magnification 10x shows positive staining for both
HPMC(A)andfibroblasts (F) with vimentin. Figure B, magnification 10x, and
magnified inset, Cytokeratins 5, 8, 18 stained HPMC(A)but notfibroblasts
(F) within the 3D model. Figure C, magnification 10x and magnified inset
Factor VIII did not stain HPMC(A) norfibroblasts (F). Fig D magnification
x100, Ber EP4 did not stain HPMC(A)cells.
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7 CHARACTERISTICS OF DIFFERENT INVASION
MODELS
The 3D in vitro models of peritoneum were invaded with cancercells, in
order to study the invasive characteristics of these cells and their interaction with
the host mesothelial cells. The ultimate aim was to show whether there was any
association between observed microscopic findings and gene expression levels
obtained from microarray studies.
Four different cancer cell lines were used. Three different concentrations
of cancer cells (104, 10°, 10° cells/ml) were inoculated in the models. Two
models were made for each concentration and cell type. The 24 models were
made in duplicate. Furthermore two models of normal, un-invaded peritoneum
were made. Thus total of 50 individual models of were created (appendix
section, Table16).
With regards to the cancercell lines, HT29 and SW480 were colonic in
origin while TMK camefrom a gastric cancer and KATO from metastatic gastric
cancer. HT29 was established from a primary well differentiated colonic
adenocarcinoma (Wang, Cheong et al., 1999) in 1964 by D Fogh (Chen,
Drabkowskiet al., 1987). KATO III gastric cancer cell line was established by
Sekiguchi in 1978 from a metastatic pleural effusion and when grown in
hamsters it behaved as a poorly differentiated tumour (Sekiguchi, Sakakibara et
al., 1978). TMK gastric cancercell lines were originally extracted from a poorly
differentiated gastric adenocarcinoma (Ochiai & Tahara, 1986). SW480 was
derived from a primary Dukes B colonic carcinoma, from a 50 year old male
patient (Hewitt, McMarlin et al., 2000). All cancer cell lines have been used in
numerousstudies about gastric (Kasuga, Tabuchiet al., 2007;Riles, Erickson et
al., 2006) and colonic cancer (Chen, Drabkowski et al., 1987;Kemperman,
Wijnandsetal., 1997)
Initially it was expected thatall cancercell lines would be gastric in origin
and the study would aim at comparing gastric cancer cells with different potential
for invasion. Whilst TMK and KATOcell lines arise from poorly differentiated
gastric cancer and metastatic cancer as stated above, there were no locally
available well or moderately differentiated gastric cancercell lines. Gastric and
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colorectal cancers originate from different organs, behave differently and have
overall different prognosis. Gastric cancers tend to invade locally and spread into
the peritoneum and they can also metastasise via lymph nodesor bloodstream to
distant organs (Dicken, Bigam et al., 2005). Haematogenous metastasis to the
liver and invasion of adjacent organs are commonpatterns of spread in colorectal
cancer (Ruo, Gougoutaset al., 2003). Having acknowledgedthis difficulty, the
two colonic cancercell lines were the best available choice, because of their well
(HT 29) and moderately (SW480) differentiated nature. However, their main
drawback wasthat any difference in behaviour in a 3D model of peritoneum, or
differences in gene expression compared to gastric cancer cell lines could be
attributed to anatomical or pathological reasons rather than intrinsic invasive
potential only.
Onthe 3D in vitro models, the four cancer cells showed different patterns
of invasion. HT29 cells grew on the mesothelial cell surface but did not invade
regardless of tumour load (Fig 12). They did not seem to be able to break the
mesothelial monolayer. This behaviour corresponded with this tumour’s well
differentiated nature. SW480 showed the most variable invasion pattern. At
lowerinitial seeding concentration (10° cells/ml) SW480 behavedsimilarly to
HT 29. However SW480 was able to invade and form rudimentary glandular
structures at higher tumour load (10° cells/ml). This feature was unique to
SW480 and confirms observations previously reported by Jayne et al. (Jayne,
O'Leary et al., 1999b).
The TMKI and KATOIII cells were visibly demonstrated a more invasive
behaviour on light microscopy. Both cell lines penetrated through the mesothelial
cell layer even at the lowest initial tumour load. Furthermore both TMK and
KATOcould digest the extracellular matrix and form distant metastatic deposits
within. In addition it was noted that fibroblasts would orientate themselves
towardsthe direction of the tumour during invasion (Fig 12).
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Figures 12 A-E Hematoxilyn/eosin
light microscopy.
Figure A. (magnification x 10) In an
uninvaded 3D model of peritoneum
HMPCtipically grew on the ECM
as a characteristic monolayer, fibroblasts (F) within the ECM. Figure B,
magnification x10, HT29 cells (B) grew on the peritoneal surface (A) but
did not invade through ECM;fibroblasts (F). Figure C, magnification x 20
SW480 cells (B) grew on the mesothelial surface (A) forming rudimentary
glandular tissue. Figure D, magnification x 10 TMK cells (B) invaded
through the mesothelial monolayer (A), and into the ECM.Fibroblasts (F)
oriented towards the invading cells. Figure E, magnification x 10, Kato cells
invaded both surface and ECM in the same fashion.
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7.1.1 IMMUNOCYTOCHEMISTRY
All 50 3D models were analysed by immunocytochemistry techniques
including use of epithelial antibodies (BerP4, CAM52, EMA,cytokeratins 8, 18),
anti-vimentin, adhesion molecules (I-CAM, V-CAM, PE-CAM)antibodies and
antibodies against extracellular molecules to further characterise basal membrane
and extracellular matrix (collagens III and IV, laminin and fibronectin).
Observed staining intensities are summarised in table 10 below and microscopic
imagesin figures 14-17.
All four cancercell lines stained with CAMS2, Cytokeratins 5, 8, 18, Ber
EP4, and EMA. Thus characterisation for all epithelial cancer cell lines was
satisfactory. Mesothelial cells from non un-invaded models reproduced the
results already stated above. The fact that Ber EP4 did not stain mesothelialcells
confirmed the mesodermalnature ofthesecells.
ICAM molecule was expressed byall invasion models as well as normal
peritoneum, with varying levels of intensity. V-CAM and PE-CAMonly stained
(very weakly) KATO models.
Collagens, fibronectin and laminin were expressed variably by almostall
models. No convincing features of basal membranes werepresent, however some
of the invasive models demonstrated the presence of a rudimentary capsule.
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 NormalTISSUE ee HT29 KATO Sw4s80 TMK
IL-CAM ++ pe +++ te +++
V-CAM none none + + none
PECAM none none + none none
BeP4 none +++ ++ ++ ++
CAMS52 +++ +++ +++ ++ ++
EMA none ++ + +H4++ +
CYTOKERATINS
++ ++ ++ = —
5,8,18
VIMENTIN +4 HH + pp a
COLLAGENIII none ++ ++ ++ none
COLLAGENIV +H ++ +++ ++ ++
LAMININ + + ++ ++ ++
FIBRONECTIN ++ +4 ++ tt ++
 
Table 10 Immunocytochemistry of 3D peritoneal models. Staining
intensities are expressed as + weak, ++ positive, +++ strong.
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Figures 13 A-E Immunocytochemistry with
epithelial antibody CAM 5.2. (Fig A,
magnification x 20) HT29 cells (A) grow on
the mesothelial surface (B). (Fig B,
magnification x 20) less intense staining by
SW480 glandular forming cells. (Fig C,
magnification x 20) TMKcells (A) invading
the peritoneum. (Fig D, Magnification x 20)
a large cluster of Kato cells (A) invading
through the peritoneum. (Fig E,
magnification x 10) epithelial glandularcells
from bowel mucosastained with CAM 5.2
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Figures 14 A-F Immunocytochemistry demonstrates the presence of staining
around groups of cancer cells resembling a membrane or capsule. Figure A,
KATOcells (A) stained with collagen IV (B), magnification x 40; Figure B,
TMKcells (A) stained with collagen III (B), magnification x 20; Figure C, TMK
cells (A) stained with fibronectin (B), magnification x 20; Figure D, HT29 cells
(A) stained with fibronectin (B), magnification x 10; Figure E, TMKcells (B)
stained with laminin (A), magnification x 20; Figure F positive control, uterus,
stained with fibronectin.
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Fig 15 A-F Peritoneal model sinmaneenchemistiy with ICAM antibody. All
figures magnified x 10. Figure A peritoneal model invaded by HT29cells. Figure
B peritoneal model invade by TMKcells. Figure C peritoneal model invaded
model by SW480 cells. Figure D, peritoneal model invaded by KATO cells.
Figure E uninvaded peritoneal model. Figure F positive control on cervix. All of
the models demostrated positive staining for ICAM.In this particular model of
invasion it was not possible to demonstrate an association between invasiveness
and ICAM levels as previously reported. In fact normal peritoneum as well as
cervix as positive control, both expressed ICAM atlocallevel
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Figures 16 A,B  Immunocytochemistry of endothelial adhesion
molecule PECAM. Fig A, magnification x 10, Kato cells (A)
produce very weak staining, compared to endothelia (A) from
control sample of uterus (Fig B, magnification x10)
Figures 17 A,B Immunocytochemistry of endothelial adhesion
molecule VCAM. Fig C, magnification x 10, SW480 cells (A)
produce very weak staining, compared to endothelia (A) from
control sample of uterus (Fig D, magnification x 40)
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8 LASER CAPTURE MICRODISSECTION
In order to analyse the molecular events taking place in the 3D models,it
was necessary to separate populations of invading cancer cells from host
mesothelial cells. The best technology available to achieve this was laser capture
microdissection (LCM). Since it was first described by Emmert-Buck, Bonneret
al in 1996, LCM has been developed to automate and_ standardise
microdissection. The principle of LCM involves placing a thin layer of
transparent film over the tissue, which is then visualised in a microscope
equipped with the laser; focussed pulses of carbon dioxide laser are applied; once
the film is removed from the tissue it will contain the cells of interest. This
technologyhasgreatly increased the reproducibility and accuracy ofthe selection
of specific target cells from a complex tissue for subsequent molecular analysis
(Bonner, Emmert-Bucket al., 1997;Emmert-Buck, Bonneret al., 1996;Simone,
Bonneretal., 1998).
To study the molecular biology of peritoneal metastasis in a 3D model of
peritoneum, 5um sections of all models were stained with haematoxylin eosin,
prior to laser capture of selected cells. For every invasion model, cancercells and
mesothelial cells were captured separately. Figure 19 demonstrates LCMresults.
Samples of cancer cells and mesothelial cells from all invasive models and
mesothelial cells from a non invaded model were collected. It was not possible to
precisely quantify numbers of captured cells per sample. Each of the 50
peritoneal models underwentlaser capture once Table. The results demonstrated
that use of LCM in this 3D model of peritoneal invasion did indeed allow
isolation of pure populationsofcells.
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Figures 19 A-D (H/E, magnification x 10) LCM of cancer cells and host
mesothelial cells is demonstrated. Figure A, Kato cells (K) invaded the
peritoneum, destroying mesothelial monolayer and growing within the ECM.
Figure B, Kato cells were captured with LCM capsandisolated from the rest of
the model. RNA wasthen extracted from the caps and amplified. Figure C
neighbouring mesothelial cells from an invaded model were captured. These
were separated from the model as shown in fig D. This method allowed
selective capture of cancer cells and host mesothelialcells in the 3D modelofin
vitro peritoneum.
a7
9 MICROARRAY STUDIES IN A 3D MODEL OF
PERITONEUM
Asstated before the hypothesis was that microscopically observed invasive
behaviour in 3D models of peritoneum, would be associated with gene
expression. The study of peritoneal metastasis in humansis difficult because of
the nature of the clinical context. Most patients with peritoneal metastases are
debilitated and have very limited life expectancy, making clinical studies very
challenging. The 3D model of peritoneum which hasa close resemblance to the
humanperitoneum wasa suitable alternative to conduct gene expressionstudies.
To my knowledge this kind of work had never been carried out before.
The experiments described here included: RNA extraction from LCM
samples described above, RNA amplification and labelling, hybridisation onto
the microarray platforms, scanning of resulting images and microarray analysis.
9.1 AMPLIFICATION
Before amplification of RNA extracted from cells captured from the 3-D
peritoneal models was performed, attempts were made to prove and validate the
method of amplification proposed wasefficient and yielded good quality aRNA,
bearing in mindthat it was not possible to assess the neither quantity nor quality
of extracted RNA from LCM samples. Using total universal reference RNA,
(Stratagene Universal Human Reference RNA, La_ Jolla, CA, US
www.stratagene.com), amplification of as little as Ing of starting RNA yielded
enough RNA (mean aRNAconcentration 0.70 ug/l, as shown in Figure 20 A.
Below Ing amplification values fell dramatically. These results were consistent
with previously published data by Stirewalt et al (Stirewalt, Pogosova-
Agadjanyanetal., 2004).
RNA quality was tested by spectrophotometry and gel electrophoresis.
Ratios ranged between 1.81 and 2.19 (Mean: 1.81). Though ratio values for
amplifications below Ing still were within the above range, electrophoresis
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demonstrated no smear for the amplified messenger RNA (Fig 20 B). This again
showedthat this methodis not reliable when attempting to amplify less than Ing
of total RNA.
Having validated this published protocol, the actual RNA from LCM
samples was amplified. A total of 12 RNA samples from laser-captured cancer
cells, host mesothelial cells and HMPC from uninvaded models were amplified
in duplicate. (Amplification raw data available in appendix sections 13.1, 13.2).
Asthe starting amount of total RNA was not known before LCM amplification,
it was uncertain whether one round of amplification would suffice. The results of
one versus two rounds of amplification, both in terms of the amount of product
(Tables 12A, B) and rangeoftranscript sizes, assessed by gel electrophoresis, are
shown below (Fig 21A, B ). In conclusion, all LCM samples needed two rounds
of amplification to reliably achieve adequate yields of good quality aRNA.
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A) FIRST ROUND OF AMPLIFICATION
 
totalaRNA Ist round Mean Median SD Max Min
Concentration 0.46 0.19 0.51 2.13 0.003
Amountin 100u1 36.61 15.50 41.09 170.54 0.27
B) SECOND ROUND OF AMPLIFICATION
total aRNA 2nd round Mean Median SD Max Min
Concentration 1.36 1.38 0.31 1.87 0.57
Amountin 1001 129.07 132.61 30.85 177.86 53.92
 
Tables 12 A, B Results of first and second rounds of amplification. After a first
round, RNA yields were often inadequate. Following a second round, amounts
close to or above | ug/ul were produced
A) FIRST ROUND OFAMPLIFICATION —B) SECOND ROUND OF AMPLIFICATION
SECOND ROUND OF AMPLIFICATION
ey a | Ree 3 Teelsize (Kb) ~ pate sue 29 32 34 39 40 42 43 44 50 55
a1
3
1.5
i]
0.75
 
Figures 21 A, B Gel electrophoresis of amplified RNA from LCM samples. (A)
Only samples in lanes 30, 33, 35, 36 produced a smear in the gel. Sizes varied
amongst samples. (B) All samples produced smears between 0.25 and 1 kb after a
second round of amplification. Although amplification in one round waspossible,
overall 2 rounds producedbetter quality results.
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9.2 RNA LABELLING
Before labelling samples, RNA concentration and purity was checked by
spectrophotometry. Reference RNA produced a mean start concentration of
0.74ug/ul (SD 0.16), and ratios between 1.8-2.1. LCM samples from peritoneal
models produced a mean RNAstart concentration of 1.19 ug/ul (SD 0.26), and
ratios between 1.8-2.4. Individual sample results are available in the appendix
section, tables 19, 20. In all cases there was enough starting material to
commence the labelling procedure. Both peritoneal model RNA andreference
RNA was of similar high quality, as assessed by electrophoresis. This was
encouraging as degradation of RNA,particularly from peritoneal samples, was a
concern.
Each sample was labelled in the same way, but spectrophotometric
assessment of label incorporation demonstrated some variability whether
coupling was performed with Cy3 or Cy5. Most striking was the variability in
RNA loss across labelling reactions. As seen in tables 19, 20 (Appendix)
recovery of labelled RNA was sometimes very poor and some samples became
unsuitable for hybridisation. Some differences were noticed between dyes.
Thus, on the whole, Cy3 coupling wasslightly better than Cy5 as shownin table
12. This difference in dye coupling efficiency has already been described, and
reported to be due to more prominent quenching of Cy5(‘t Hoen, deet al., 2003).
The same amount of Cy3-sample and Cy5-reference RNA were combined for
each hybridisation on eachslide in all cases.
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9.3 HYBRIDISATION ON MICROARRAYS
Hybridisation is the process of applying the previously labelled aRNA
from all samples into the microarray slides. As a result genes from the samples of
interest will couple or hybridise to complementary oligonucleotides printed on
the MWGcancerarray slides. This step is crucial since poor hybridisation
generated from poor quality samplesor slides would generate invalid data if any.
Previous attempts at in-house manufacture of spotted microarray slides by
colleagues proved unsuccessful. For this reason it was decided, despite the very
high cost, to perform all microarray experiments in commercialslides.
Equally important to processing the samplesis the adequate choice on the
numberof hybridisations per sample including biological and technicalreplicates
in a given numberofslides. This is known as hybridisation design. This process
is crucial to provide not only a cost effective use of slides, but to potentially
obtain the best results from the experiments. In this project the reference design
was preferred. It is a very popular method which can be found in many
microarray publications. The principle is based on the level of expression of any
gene in a sample which can be related to the expression of that gene in the
commonreference, as measured on that slide. Subsequently, expression levels of
a gene on different slides may be compared using the commonreference to
control for sources of variability, amongst spots that affect both channels
similarly (Dobbin & Simon, 2002b). The reference design is a practical and
popular choice for microarray studies using two colour platforms (Kerr,
Serikawaet al., 2007). Total universal reference RNA containing total RNA from
10 different humancell lines (Stratagene Universal Human Reference RNA, La
Jolla, CA, US www.stratagene.com) was used as the reference to perform the
hybridisations.
Experiments were performed as summarised in Table 13. 3 Initially 50
slides were purchased, howeverthree slides had to be discarded. For each cancer
and mesothelial cell model there were two independent biological replicates
yielding 18 different RNA samples. For each sample twotechnical replicates at
least were performed. Some sampleshadthree.
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CANCER CELLS HT29 SW480 TMK KATO
 
Biological replicates 2 2 2 Z
Technicalreplicates 233 3;3 333 3;3
Total number of samples 5 6 6 6
MESOTHELIAL CELLS HMPC HT29 SW480 TMK KATO
 
Biological replicates 2 2 2 2 2
Technical replicates 233 1;3 233 2;3 2;3
Total number of samples 5 4 5 5 5
Table 13 Replicate classification. For each sample there were two biological
replicates and these would provide one, two or three technical replicates.
Tehcnical replicates are shown as numberofreplicates per biological sample,
separated by(;).
After hybridisation and incubation each plate was washed and then
scanned. Examples of the images generated showing combined signal for Cy3
and Cy5 is shown below (Figs 22A, B). Overall the results were very
satisfactory. Using relatively low gains, the intensity at which the scanner
provided an image, it was possible to produce good quality images, with even
spot distribution, low background noise and good spot intensities throughout
each array. In fact only three slides with poor image quality were discarded.
Below a typical image of a cancer array is displayed to illustrate this. The
quality of all 47 arrays was similar.
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Figures 22, A,B Microarray
images. (A) whole array and (B)
magnified view. Following
hybridisation and incubation
each array slide was scanned.
Images were produced from the
lowest scanner intensity gain
that would allow a combined
signal for Cy3 and Cy5 channels,
hence minimising background
and avoiding photo-bleaching.
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9.4 MICROARRAY ANALYSIS
Thefirst step in microarray analysis is to convert the images obtained by
the scanner into numbers. This process is facilitated with the use of computer
software which performs this process, known as feature extraction. The
programmedetermines which pixels within the scannedareaare part of a feature
or spot and whichare part of the background, outside the spots. The best image
quality translates into most successful results. For this purpose, scanned images
were analysed with Genepix Pro 6.0 software, Molecular Devices Corporation,
California, www.moleculardevices.com/logos). At the time this programme was
the only of its kind that had an automatic spot detection feature, thus reducing
error in the process of spot alignment, commonly faced during manual grid
alignment. Using a compatible gene identification file supplied by MWG
Biotech, London, automatic spot or feature detection was used, and data from
both channels was linked to the appropriate gene annotation information. Thus,
at this point images were translated into numbers. Microarray spot quality
control was performed following the parameters, described in materials and
methods. These allowed exclusion of poor spots based on poor signal, which
would provide false negative results. Also, excessive noise misinterpreted as
signal could potentially produce false positives. Furthermore, poorly shaped
spots or those with non-uniform pixel distribution were too excluded. Such
exclusion process was knownasflagging. Any flagged spots were subsequently
filtered and excluded from further analysis.
Further analysis was carried out with BRB-Array tools (version 3.3.0)
described by Simon et al (Simon, Lam et al., 2007). This is a free software
package from the Biometric Research Branch, Division of Cancer Treatment and
Diagnosis, National Cancer Institute, Rockville, Maryland, USA.It is free and
available online to download as application to be used with Microsoft Excel.
Once each array file had been processed by Genepix as above, including
flagging, but not normalised, these were loaded onto BRB astext files, which
contained information on gene ID, median and standard deviations for signal
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‘Intensity of each spot and its background. In addition the programme required a
Microsoft Excel experimental descriptor file. This contained the names of the
samples to which the files would subsequently be linked. The files were then
loaded into BRB-Arraytools in class comparison mode. Data normalisation was
performed before the analysis. A submenu named “filter and subset the data”
provided the normalisation options. The programme offered two options: to
normalise using the median over house-keeping genes or to normalise over the
entire array, using median array asreference. In this project, normalisation was
performed over the entire array. Median centring, as previously described by
Eisen et al (Eisen, Spellmanet al., 1998), allows removal of any systematic bias
in expression between different cell-type models and facilitates comparison
across columns. Once the data was flagged and normalised, the analysis was
performed in two different approaches, hierarchical clustering and class
comparison.
Cluster analysis was performed on all the gene expression profiles
generated in the arrays, for both the cancer and the host mesothelial group. The
results are show in the figure below. This conventional analysis looks at the level
of similarity/dissimilarity between individual samples. The results are expressed
as a dendrogram (Figures 23, 24), where the distance between branches is
proportional to the level of “relatedness” detected by the software.
Two main findings were apparent amongst the results. All technical
replicates demonstrated high index of correlation, appearing next to each other
within the dendrogram. These results were very encouraging for both the cancer
and host mesothelial cell groups. Considering that these technical replicates were
identical samples, lead to the conclusion that the experiments were performed in
a robust and consistent manner. The process of laser capture, RNA isolation and
amplification, label and hybridisation were performed on different days, further
reinforcing the strength of these results. Unfortunately these findings were not
reproduced within biological replicates. Within the cancercell group, noneofthe
biological replicates appeared to be linked to one another. Only samples 15 and
39, both SW480 invasion models showedslight correlation. If gastric versus
colorectal cancer were compared, samples 33 (TMK) and 51 (KATO), both
gastric cancers had a correlation value near 0.5. Samples 15 (HT 29) and 21
(SW 480) correlated somewhat, with a value near 0.2. Another interesting
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finding is the position within the dendrogram of samples 9 (KATO) and 45 (HT
29). The possibility of both being mislabelled cannot be completely excluded. If
that wasthe case, the final result would be that gastric and colonic cancers group
together within the dendrogram. Howeverthe processoflabelling was rigorous.
CorrelationA) CANCER CELL INVASION MODELS1 os O68 O4 O2 oO -02
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Figure 23 A Cancer cell dendrogram Heat map showing cluster analysis
performed on gene expression data generated from arrays, for the cancercells.
Samples were clustered by comparing their expression profiles across the set of
genes. This approach identifiesH the level of similarity/dissimilarity between
individual samples and results were expressed as a dendrogram. The distance
between branchesis proportional to the level of “relatedness” between samples
detected by the software.
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Figure 23 B Mesothelial host cell dendrogram Heat map showing cluster
analysis performed on gene expression data from the arrays, for the host
mesothelial cells. Samples were clustered by comparing their expression profiles
across the set of genes. The software identified the level of
similarity/dissimilarity between individual samples and results were expressed as
a dendrogram. The distance between branches is proportional to the level of
“relatedness” between samples detected by the software.
Within the host mesothelial group the results were similar. Technical
replicates again grouped next to each other. Only biological samples of
peritoneum invaded by SW 480 grouped together. Although host mesothelial
cells invaded by HT 29 were grouped next to uninvaded peritoneum,at least one
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model invaded by KATOcells also grouped next to uninvaded peritoneum.
Overall there was no clear correlation amongst samples, except for SW 480,
regarding tissue type or invasion pattern.
The most immediate criticism would be the lack of microarray
experiments due to costs. If it was possible to produce far more biological
samples, including whether available, invaded models by other gastric and
colonic cancercell lines, the results would be morerobust.
Further analysis was performed by the class comparison approach, which
allowed identification of differentially expressed genes among samples, both
biological and technical replicates. The principle of class comparison is based on
the use of statistical methods in order to test a hypothesis and determine which
genesare statistically significant (different) across the groups of interest. This
statistical approach aimed at identifying gene changes associated with the
biological processes taking place, while minimising false discovery rates or the
presenceof false positive results. The class comparison analysis was performed
with the F test (a generalisation of the t-test which allows comparisons amongst
groups) separately for each gene using normalised log ratios from the arrays. The
random variance version of the F-test was used, because the numberof samples
per class was small. Random variancetests take into account information among
genes of the within-class variance in log-ratios.
Another issue commonly faced during microarray analysis is the finding
of a proportion of genes which may appeardifferentially expressed although they
are not of biological significance, also known as false discovery rates. When
multiple independent tests are carried out on a given sample, the likelihood of
false discovery doubles with each additional test. Although mathematical
approaches such as Bonferroni’s correction test, where the accepted test-wise p
value is divided by the numberof independenttests (Bonferroni CE, 1936), try to
compensate for this, they may prove to restrictive in microarray analysis,
resulting in reduced false discovery rates at the price of also reduced biologically
significant data. Other statistical approaches use more conservative correction for
multiple testing than Bonferroni’s. These rank results based on their p values and
accept as best those with the smallest p values, until they satisfy certain
mathematical characteristics, known as step down analysis (Benjamini Y &
Hochberg Y, 1995;Holm, 1979). While these approaches improve sensitivity
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they compromise on false discovery rate. More recently, permutation tests have
been developed to calculate false discovery rates in class comparisons.
(Radmacher, McShaneetal., 2002). In this approach each individual sample is
analysed by comparing it to other samples belonging to different classes,
identifying genes that are differentially expressed and ranking these in order of p
value. Then the same sample is given the “wrong” classifier, and the
comparisons are repeated generatinga list of “differentially expressed” genes and
their associated p values. Assuminga perfect dataset, in this second permutated
analysis, there should be nosignificantly different genes. The number and
significance of the “differences” observed during the permutated analysis allows
the software to calculate the level of error present in the dataset. (In contrast the
previously mentioned step down analysis only estimates the error). By analysing
the dataset reiteratively, the number of false discoveries can be controlled much
more tightly and accurately while maximising sensitivity. The algorithms used
for these calculations have been tested extensively on both simulated data and
publicly available real life gene expression data (Korn EL, Troendle JF etal.,
2004).
In this project the p-value was set at p<0.001 with a maximum false
discovery rate set at 10 genes or 10% of the total of the genes identified as
differentially regulated, in order to maximise the sensitivity of the study and
minimise the rate of false discoveries. In the cancer cell group 139 genes were
differentially regulated. Within the host mesothelial cell group 104 were included
(Appendix sections 13.3, 13.4). Genes were selected that would be differentially
expressed in either ascending or descending order regarding the invasive
behaviour of the class they belong. The results are displayed below in tables 14,
15. The cancer cell group displayed four genes of interest, three of them up-
regulated and one downregulated with malignancy. In the host mesothelial cell
group 15 genes were up-regulated and 3 were down-regulated.
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10 GENETIC CHARACTERISATION OF DIFFERENT
INVASIVE PHENOTYPESIN A 3D MODEL
10.1 CANCER CELL GENE EXPRESSION
Whenresults of microarray studies had been normalised and analysed as
described above, genes were selected as potentially relevant to peritoneal
metastasis and invasion based on the correlation between gene expression and
the observed invasive behaviour of the cancer cells in the models described
earlier. A total of 139 genes were identified following analysis, using the F-test
with a univariate random variance model. Nominal significance of each
univariate test was less than 0.001 and false discovery rates were also less than
0.001. Genes selected from the above included those following a gradient pattern
of expression. They were either up or downregulated depending on degree of
invasion, previously shown in light microscopy. Only three genes from cancer
cells followed an ascending and one a descending pattern of expression. For
instance, the protein kinase, pctkl, (NM_033018), was differentially more
expressed in HT 29 and gradually less with other more invasive lines.
Conversely, DEK oncogene (NM_003472) was gradually more expressed in
Kato cells type than the other cell types. Cutaneoust-cell lymphoma tumour
antigen se70-2 (NM_022118) and retinoic acid receptor responder tazarotene
induced 3; rarres3 (NM_004585) were differentially far more expressed by the
malignantcell lines TMK and KATOthan HT 29 and SW480.
Although the role of DEK and relevance to clinical practice is poorly
understood there were somestudies reporting its involvement with cell cycle and
senescence. DEK oncogene encodes a protein which binds to cruciform and
superhelical DNA and induces positive supercoils into closed circular DNA and
is also involvedin splice site selection during mRNA processing. Chromosomal
aberrations involving this region, increase expression of this gene and the
presence of antibodies against this protein were all associated with various
diseases. Wise-Draperet al found the human DEKproto-oncogeneto behaveas a
senescenceinhibitor, in their studies with Human Papilloma viral oncogenes E6
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and E7. Specifically DEK message and protein levels were repressed during
cervical cancer cell senescence when induced by either E2 overexpression or
E6/E7 interference. They reported that DEK contributed to extended cell life
span and potential elevated risk of carcinogenic progression over time(Wise-
Draper, Allen et al., 2005).
Retinoids are involvedin cell growth and differentiation activities. This is
mediated by specific nuclear receptor proteins that are members of the steroid
and thyroid hormone receptor superfamily of transcriptional regulators. Growth
inhibitor retinoic acid receptor responder, tazarotene, is used in the treatment of
hyperprolipherative skin conditions such as psoriasis (DiSepio, Ghosn et al.,
1998). It is also thought act as a tumour suppressoror growth regulator in gastric
epithelial cells, and their inhibition by hypermetilation, commonin the elderly,
cause this and other genesto lose their role, making gastric cancer morelikely in
that age group (So, Tamuraet al., 2006).
The protein kinase, pctkl, (NM_033018) gene encodes for a protein
which belongs to the cdc2/cdkx subfamily of the ser/thr family of protein
kinases. It may play a role in signal transduction cascadesin differentiated cells.
However,its role in gastrointestinal cancer is unknown.
In summary, very few genes demonstrated a pattern of expression that
could be associated with observed microscopic findings. Despite the relevant
findings described above, further experiments could provide a more robust
answerto the molecular biology of peritoneal metastasis.
10.2 HOST MESOTHELIAL CELL GENE EXPRESSION
A total of 104 genes were identified following analysis, using the F-test
with a univariate random variance model. Nominal significance of each
univariate test was less than 0.001 and false discovery rates were also less than
0.001. Within the results a number of genes were selected which followed a
gradient pattern of expression. They were either up or downregulated depending
on degree of invasion, previously shownin light microscopy. This resulted in 18
genes being selected (table 15). 15 genes were significantly upregulated in the
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most aggressive cancer cell lines (Kato and TMK), and 3 showed a decreased
gradient of expression. It was expected that non invaded HPMC (mesothelial
cells only) would behaveas the baseline and that once invasion took place genes
would show an ascending or descending pattern of expression. Howeverthis did
not happen and the reasons for this were unclear. Overall HPMC expression
levels mostly fell in between those of host mesothelial cells invaded by cancer
cells.
Using the gene annotation tool from BRB array tools, gene functions
were sought and their relevance to the process of invasion identified whether
possible. Fatty acid binding protein psoriasis-associated; fabp5 (NM_001444)
has a high specificity for fatty acids. This gene encodes the fatty acid binding
protein found in epidermal cells, and wasfirst identified as being upregulated in
psoriasis tissue. Fatty acid binding proteins are a family of small, highly
conserved, cytoplasmic proteins that bind long-chain fatty acids and other
hydrophobic ligands. It is thought that FABPs roles include fatty acid uptake,
transport, and metabolism. FABPs have been reported to be involved in the
primary response of liver parenchymal cells to Western-type diet feeding, and
may play an importantrole in the primary protection against the cellular toxicity
of cholesterol, free fatty acids, and lipid oxidants (Hoekstra, Stitzinger et al.,
2006). Howeverthere are no reports linking this gene with neoplasia. Althoughit
wasnot possible to link this gene to the process of invasion, HPMC showed
highest levels than any other invaded host mesothelial cell, or in fact than any
gene in the list. Mesothelial cells invaded by Kato showed very high levels of
expression, while other cell lines had much lowerlevels (p<le-07).
Mutl homolog | (mlhl, NM_000249) wasidentified as a locus frequently
mutated in hereditary nonpolyposis colon cancer (HNPCC). Defects in mlh1 are
the cause of hereditary non-polyposis colorectal cancer type 2 (hnpcc2). Most
families with clinically recognized HNPCC have mutations in either mlh1 or
msh2 genes. HNPCCis an autosomal, dominantly inherited disease associated
with marked increase in cancer susceptibility, characterized by a familial
predisposition to early onset colorectal carcinoma and extra-colonic cancers of
the gastrointestinal, urological and female reproductive tracts. HNPCC is
reported to be the most common form of inherited colorectal cancer in the
western world, and accounts for 15% of all colon cancers. Lower expression of
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this gene is associated with development of colonic adenomata and colorectal
carcinoma(Sidelnikov, Bostick et al., 2009). In the 3D models of invasion Mlh1
was least expressed by HPMCinvaded by HT 29, then SW480, TMK, Kato and
highest levels were found on uninvaded peritoneum (p<1e-07).
A gene involved in DNA damage and repair was Rad 23a. The protein
encoded by this gene is one of two human homologs of Saccharomyces
cerevisiae Rad23. This protein is involved in DNA damage recognition,
nucleotide excision and repair. Thus it provides subsequent regulation of protein
stability. Rad 23 proteins are knownto regulate p53 stability in unstressed cells
and control apoptosis (Kaur, Pop et al., 2006). Little is known aboutthe precise
mechanism of action of Rad23 in gastrointestinal cancer. However a few reports
exist involving other neoplasms. Shen et al found positive correlation between
expression of a Rad23 polymorphism and development of lung cancer in a
population highly exposed to indoor smoky coal emissions (Lee, Shen etal.,
2007). Steinberg et al found that downregulated Rad23 UV excision repair gene
and the Growth Arrest and DNA Damage gene (GADD45) were found in
patients with melanoma (Steinberg, Hubbardet al., 2009).
Annexin A2 was more expressed by host mesothelial cells invaded by the
invasive gastric cancercell lines TMK and Kato, and less by HT29 and SW480.
Annexins are a family of calcium dependent proteins with the ability to bind
membrane phospholipids and other anionic polymers, mostly
glycosaminoglicans, such as heparin and heparin sulphate and have been
implicated in many functions suchascell signalling, ion transport, inflammation,
apoptosis, fibrinolysis and angiogenesis (Shao, Zhanget al., 2006). The role of
these genes in neoplasia has been documented. Lenighk et al reported that
downregulated levels of annexin 2 were present in prostate cancer compared to
normal prostate epithelia or benign prostatic disease (Lehnigk, Zimmermannet
al., 2005). Sharmaet al reported that annexin 2 was a promoter of breast cancer
growth and angiogenesis via conversion of plasminogen to plasmin (Sharma,
Koltowski et al., 2006). More interesting is a role for annexin described as
vascular carcinomatosis or tumour proliferation on the vascular intima that
replaces normal epithelium (Madoiwa, Someyaet al., 2007). This was described
by Madoiwaetal in a small study with three patients suffering metastatic renal
cell carcinoma. These patients presented with coagulopathy with low plasma
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fibrinogen and high levels of products of degradation of fibrinogen and fibrin.
Areas of vascular carcinomatosis presented high levels of annexin 2. Annexin 2
has also been linkedto gastric carcinoma, and correlation found with lymph node
invasion and metastasis (Emoto, Sawada et al., 2001). However there are no
reports to date of annexin 2 in peritoneal metastasis. Host mesothelial cells
showed an upregulated pattern of expression in response to invasiveness. Non
invaded peritoneum however, showed higher level of expression than HT29,
SW480 and TMKinvasive models.
a-tubulins 1, 2 and B-5 all were differentially expressed by peritoneal
cells from invaded and non-invaded models. a-tubulin 1 had a replicated spot.
Gene expression levels in both spots showeda similar pattern. This was not the
case with a-tubulin 2, where only 1 spot showed a differential pattern of
expression. Tubulins form structures known as microtubules which are an
important componentof the cytoskeleton along with microfilaments (actins) and
Vimentin (Source: Entrez Gene,www.ncbi.nlm.nih.gov ). These genes play
therefore an important role in maintaining cellular adhesion. Adhesion is
essential for the maintenanceoftissue architecture. Loss of adhesionis a feature
common in many tumours. A visible finding during peritoneal invasion was the
loss of the mesothelial monolayer, thus allowing cancer cells to enter the
extracellular matrix. This was most marked on the TMK and Kato invasion
models. In contrast gene expression patterns did not quite reflect the same
picture. While there was a gradient of expression, this was opposite to the
microscopic findings. The expected result would be a down-gradient of
expression. Also non invaded models showed higher expression levels than the
colonic invasion models but lower than Kato which was again contrary to the
microscopicfindings.
Another gene of interest was the inhibitor of DNA binding dominant
negative helix-loop-helix. The protein encoded by this gene belongs to the
inhibitor of DNA binding (ID) family, members of which are transcriptional
regulators that contain a helix-loop-helix (HLH) domain but not a basic domain.
Members of the ID family inhibit the functions of basic helix-loop-helix
transcription factors in a dominant-negative manner by suppressing their
heterodimerization partners through the HLH domains. This protein may play a
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role in negatively regulating cell differentiation (Source: Entrez, NCBI,
www.ncbi.nlm.nih.gov.)
A probable gene of interest previously isolated in B cell chronic
lymphocytic leukaemiacells is B cell translocation gene 1 BTG1 (NM_001731).
This gene was upregulated in HT29 and SW480 compared to uninvaded
peritoneum and downregulated in TMK and Kato. BTG1 belongs to a family of
antiproliferative genes. Its expression is maximalin the GO/G1 phasesofthe cell
cycle and downregulated whencells progress through G1 (Source: Entrez, NCBI,
www.ncbi.nlm.nih.gov.). A role in angiogenesis has been reported for this gene
as its up regulation led to endothelial cell proliferation and neovascularisation in
an in-vitro model of angiogenesis (Iwai, Hirata et al., 2004). There is no
published data linking this gene with gastrointestinal malignancy.
Aspartate B-hydroxylase isoform a (asph, NM_004318) gene is thought to
play an important role in calcium homeostasis, by regulating calcitum release
from the endoplasmic and sarcoplasmic reticulum. The gene is expressed from
two promoters and undergoes extensive alternative splicing, thus leading to
varied functional properties. Some isoforms have been implicated in metastasis,
though there are no reports regarding peritoneal metastasis. The gene has been
reported in gastrointestinal cancer, mostly in cholangiocarcinoma, where the
gene was detected in these patients with RT-PCR (Feldmann, Nattermann etal.,
2006).
Overall, a number of genes were identified with patterns of expression
which corresponded with the previously shown microscopic findings. Some
relevant cell roles and functions were identified including adhesion, cell cycle
control, angiogenesis, apoptosis, cell signalling and transport. It was not possible
to assess how those changes in invaded host mesothelial cells related to a non
invaded model. The mostlikely explanation is that the numberof both biological
and technical replicates was inadequate. Further experiments would probably
strengthen the data and possibly provide other potential candidate genes not
identified here.
Howeverit has been possible to demonstrate that the in vitro 3D model of
peritoneal invasion is a suitable source to study peritoneal metastasis using
microarray technology.
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11 REAL TIME PCR VALIDATION
Extensive data in the literature indicates that multiplexed hybridization
based DNA/RNA measurements, including those obtained with microarrays, are
often unreliable. This is due to many factors; in case of oligonucleotide arrays the
primary concerns are about the specificity of the gene specific oligo present on
the array and errors introduced during the complex multi-step sample
amplification procedure. In addition, the high numberof parallel observations
made during array experimentsraises the possibility of randomly occurring false
positive results. Thus, findings from microarray experiments are often regarded
as “trends”, which require further validation by alternative, preferably non-
hybridization based approaches. Depending on the constraints of the experiments
immunohistochemistry, RNAse protection assays or quantitative PCR are used
most frequently for the purposes of this confirmatory work. However, as RNAse
protection assays require large amounts of starting material, they could not be
performed with laser captured samples. Given that the laser capture process
removed the relevant cells from the models, antibody based detection systems
could not be used either. To independently confirm the findings of the array
hybridization studies quantitative real time PCR experiments were carried out.
Due to the limited amounts of starting material, as well as monetary and time
limitations, it was impossible to confirm every array finding. Based on a
preliminary analysis of the data three genes of potential interest were selected
and gene specific primer/Taqman probe sets for these were obtained from a
commercial source. The abundance of the mRNA species of these genes was
quantified in the samples. The results of this work are presented here.
To test whether the primer sets designed by Qiagen (Qiagen, Crawley,
West Sussex, UK, www.giagen.com) were working andto check the efficiency
of the amplification, universal reference RNA (Stratagene Universal Human
Reference RNA, La Jolla, CA, US www.stratagene.com) wasreverse transcribed
and a dilution series of the cDNA product was set up, as described in the
Materials and Methodssection. Quantitative PCR reactions were run amplifying
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aliquots of these pre-diluted standard samples with the gene-specific primersets
to establish a standard curve and calculate the efficiency of the amplification
process. Thereafter, cDNA derived from laser captured samples was run,
together with the standard curve, to measure mRNAlevels in individual laser
captured samples as detailed in Materials and Methods. Quantitative PCR
experiments were multiplexed (dual channel) single tube amplifications, to
eliminate pipetting errors. The housekeeping gene used throughout was GAPDH,
with primers and Taqman probe from the same commercial source.
11.1 RT PCR RESULTS
There were three genes selected for real-time PCR validation based
potential relevant pathways in the process of peritoneal metastasis (ECM
proteolysis, apoptosis and cystoskeletal disruption). These were cathepsin k
(NM_000396), vimentin (NM_003380) and caspase 8 (NM_033356). Following
the analysis of microarray data with BRB array tools, only one gene from the
above, cathepsin K wasdifferentially expressed by cancercells. Geometric mean
values for HT29 (0.16), SW480 (0.16) and KATO (0.13), were similar, whereas
TMKcancer gene expression levels were considerably higher (1.90), p<le-07.
However cathepsin K was not found to be differentially expressed by invaded
host mesothelial cells. Therefore, the results of RT PCR presented here could not
be associated to the microarray data. RT PCRresults are presented to show that
RT PCR, regarded as a gold standard test, may be performed to confirm gene
expression results extracted from microarray data. This would be a requirement
for publication of microarray studies in most high impact journals.
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11.1.1 Cathepsin K
Cathepsin K is a lysosomal cysteine proteinase. Under physiological
conditions the protein is primarily present in osteoclasts where it contributes
bone remodelling, as mentioned earlier, this gene is expressed in certain tumours,
including breast cancers, where it has been suggested to contribute to
invasiveness.
Duringinitial primer/Taqman probetesting the abundance ofthis message
washigher than that of the housekeeping gene. During the amplification of the
commercial reference mRNA sample the cathepsin k amplification curve (figure
24 A) crossed the detection threshold (C;) sooner than the GAPDHcurve(figure
24 B) indicating that the abundance of this mRNA washigher than that of the
housekeeping gene used.
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Figures 24 A,B Threshold fluorescence values for cathepsin K determined by Rotorgene, following the log-
transformation of fluorescence measurements for each channel (A Fam channel, B Joe channel). (X axis shows number
of cycles at which threshold values are reached, Y axis showsfluorescence valuesin log scale. Standard curvesfor each
channel, on the right, generated using 2-fold serial dilution of the reverse transcribed Universal mRNA standard. Panel
A, cathepsin K amplification, panel B GAPDH housekeeping amplification (Y axis, CT is the threshold cycle; x axis is the
concentration in log scale) red dots are the geneofinterest, blue dots are reference RNA.
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Fig 25 Host mesothelial cell cathepsin K expression in the 3D models.
Bars show Ct detection threshold ratios between the gene of interest (GOI)
versus housekeeping gene (HK) Cathepsin K/GAPDH ratios for the
samples. Error bars show standard deviation for each group of samples.
Numerical data available in appendix
The analysis of the standard curves shown in Figures 24 A, B (data in
appendix section13.6) indicated that the amplification of the cathepsin k gene
wasslightly less efficient than that of GAPDH (R Fam channel 0.98, R Joe
channel 0.99). The mesothelial cell derived cDNA samples derived from non-
invaded and invaded peritoneal models were run together with the dilution
standards. The analysis of these curves has shown that the detection threshold
(C,) for the cathepsin k gene product was 1.2 cycles higher than that of GAPDH
in the universal reference RNA sample. Similarly, in the non-invaded mesothelial
samples the difference in C; values was 1.18. In contrast the expression was
higher in both TMK and KATOinvading models. However HT 29 and SW480
invasive models showed lower levels of cathepsin K than non invaded
peritoneum (Fig 25). These data confirm that although the expression of
Cathepsin K showeda gradient pattern of expression in invaded mesothelialcells
the level, only KATO and TMKwereslightly higher than reference RNA or
normal peritoneum. As this gene was not differentially expressed by the
microarrays, it was not possible to establish any association.
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11.1.2 Vimentin
Vimentin is an important component of the cytoskeleton along with
microfilaments (actins) and microtubules (tubulins), (Source: Entrez Gene,
www.ncbi.nlm.nih.gov ). Invaded mesothelial cells had shown a pattern of
inverse association of expression versus microscopic level of invasion, in
previous microarray analysis. Current analysis did not show this gene to be
differentially expressed by invaded mesothelialcells
Vimentin primer/Taqman probe testing the abundanceof this message was
higher than that of the housekeeping gene. Amplification figures and standard
curves (figures 26A, B) (data in appendix 13.7) for this genes showed that
vimentin gene (FAM channel) crossed the detection threshold (C,) sooner than
the GAPDH,although this difference is less obvious than for the previous gene
cathepsin K. A separate grey curve not crossing the detection threshold in the
FAM channel corresponded to a negative control. The standard curves also
showed that vimentin amplification wasslightly less efficient (R=0.93), than of
GAPDH (R=0.96).
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Figures 26 A,B Threshold fluorescence values for vimentin determined by Rotorgene, following the log-
transformation of fluorescence measurements for each channel (A Fam channel, B Joe channel). (X axis
shows numberof cycles at which threshold values are reached, Y axis shows fluorescence values in log
scale. Standard curves for each channel, on the right, generated using 2-fold serial dilution of the reverse
transcribed Universal mRNA standard. Panel A depicts the amplification results of the vimentin k target gene
while panel B shows the GAPDH housekeeping gene curves measuredin the sametest tubes.
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Below are shown the detection threshold (Ct) ratios for vimentin (Fig 27).
Although abundance of vimentin was higher than that of the housekeeping gene
used, Values were fairly similar across the samples, and on this occasion there
wasno obviousgradient of expression. On this occasion no uninvaded peritoneal
models had been run along the samples for comparison. Although they would
have not necessarily contributed to the results, it is acknowledged that their
analysis should have been included for the sake of completion.
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Fig 27 Host mesothelial cell vimentin expression in the 3D models. Bars
show the Ct detection thresholds between the gene of interest (GOI)
Vimentin and the housekeeping gene (HK) GAPDH,for the samples. Error
bars show standard deviation for each group of samples. No Standard
deviation available for HT 29 as only two models were run. Numerical data
available in appendix
11.1.3 Caspase 8
Caspase 8 is an apoptosis related gene, directly involved in the extrinsic
pathways in apoptosis. This pathway is activated following ligand binding to
receptors of the tumor necrosis factor (TNF) superfamily, and activation of the
caspases. Disruption of the normal apoptotic pathways may lead to the
development of cancer (Hajra & Liu, 2004). This gene had also been expressed
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by invaded mesothelial cells in previous microarray analysis. Howeverfollowing
current analysis this gene wasnotdifferentially expressed.
The primers and Taqman probe amplifying the Caspase 8 gene were
tested identically to that described for the two previous genes. However, as
shown in Figure 28A, B while the universal reference RNA showed good
amplification with these reagents, none of the laser dissected mRNA samples
showed measurable levels of Caspase 8. Figure 28A demonstrated how series
of reactions went abovethe threshold, after 25 to 30 cycles. These corresponded
to the reference RNA. None of the samples yielded results above the threshold.
Equally the standard curve failed to show any of the samples amplification,
normally represented by red dots. Results in the Joe channel (Fig 28B) showed
better results for GAPDH amplification in both reference RNA and samples. In
summary assays for CASPASE8 did notreturn technically acceptable results for
samples; further analysis of these amplifications was subsequently not carried
out.
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Figures 28 A,B Threshold fluorescence values for caspase 8 determined by Rotorgene,following the log-
transformation of fluorescence measurements for each channel (A Fam channel, B Joe channel). (X axis
shows numberof cycles at which threshold values are reached, Y axis showsfluorescence values in log
scale. Standard curves for each channel, on the right, generated using 2-fold serial dilution of the reverse
transcribed Universal mRNA standard. Panel A depicts the amplification results of the caspase 8 target
gene while panel B shows the GAPDH housekeeping gene curves measured in the sametest tubes.
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11.2 SUMMARY
The results of the PCR validation studies were disappointing in that they
could not validate any of the present data. The process of optimisation of the
real-time PCR reactions is costly and time-consumingandit is unfortunate that
these experiments were limited both by costs, and by the time available to
complete the work. This meant that the genes for the purposes of the PCR
confirmation were selected based upon a previous rudimentary analysis not at the
completion of the current full analysis of the comprehensive array dataset. This,
unfortunately, greatly limited the biological relevance of the selected genes. Thus
there were practical reasons why many of the intending validation experiments
were not completed and did notyield useful results.
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12 DISCUSSION
A three-dimensional model of peritoneum wasthe platform of choice to
study the molecular biology of peritoneal metastasis. Immunocytochemical
studies and analysis of gene expression in both cancer cells and mesothelial cells
were conducted to investigate the mechanismsofperitoneal metastasis.
The optimal method for isolation of HPMCisolation was determined and
3D model was constructed, as described by previous authors, and characterised
by light microscopy and immunocytochemistry.
HPMCisolation was a complex process. Despite previous reports in the
literature, which reported successful HPMC isolation, it was necessary to
compare someof the published methods to consistently obtain HPMCcells from
tissue samples. Previously, tissue culture models of the peritoneum had been
developed using isolated human mesothelial cell monolayers alone, or in
combination with a variety of connective tissue supports (Jayne, Perry et al.,
2000;Sawada, Shii et al., 1994) . Though HPMC could be obtained from
commercial sources (Coriel Cell Repositories, Camden, New Jersey)(Casey,
Koch et al., 2003), most authors harvested HPMC from omental tissue
(Stylianou, Jenner et al., 1990;Zhang, Pettengell et al., 1999) or peritoneal
effusions (Rieppi, Vergani et al., 1999;Sakata, Shigemasaet al., 2002) obtained
from local clinical sources. Satisfactory isolation and growth of HPMCis crucial
to the success of any tissue culture model used. Commonly encountered
problems include poor yield of HPMC from different isolation techniques, and
contamination of HPMC with fibroblasts which grow much more rapidly and
dominate the combined cell preparations making them unsuitable for use in
studies aimed at understanding mechanismsofdisease in the peritoneum.
Isolation of HPMC from omentum usually requires protease digestion to
release HPMC from the underlying connective tissue. Use of different
concentrations of trypsin for varying lengths of time has been reported. Some
studies reported success digesting omentum with trypsin 0.25% for 20 minutes
(Mizutani, Kofuji et al., 2000b) , others used 0.05% trypsin for 5 minutes
(Bittinger, Brochhausenetal., 1997).
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In order to develop the models, a total of 40 HPMCisolation experiments
were performed. 11 samples underwent digestion with 0.05% trypsin for 20
minutes, as described in materials and methods. None of them yielded any
results. However when 0.25% trypsin was used instead on 29 omental samples
(15 samples digestion time 10 minutes, and 14 samples digestion time 20
minutes) the results were better. Only 4 out of 15 (26%) samples digested for 10
minutes yielded a pure mesothelial population. When omental tissue was
digested with trypsin 0.25% for 20 minutes, 10 out of 14 (71%) samples yielded
satisfactory growth. Although the overall number of experiments was notlarge,
HPMCisolation with 0.25% trypsin for 20 minutes produced significantly better
results than the 10 minutes group.(Fisher’s exact test p=0.02).
The fibroblast contamination of isolated HPMC was present in the
methods assessed. Though nostatistically significant differences were observed
among the 0.25% trypsin digestion groups (10 minutes group, 8 contaminated
out of 15 (53%); 20 minutes group, 3 out of 14 (21%), fibroblast contamination
remains a major issue in performing or interpreting any studies using isolated
HPMC.The fibroblast contamination observed mightindicate that the peritoneal
mesothelial cell monolayer present in the omentum wasdisrupted at some point
during collection, thereby increasing the chances that subsequent trypsin
digestion and centrifugation would release fibroblasts in addition to HPMC. To
counteract this, after removal from the peritoneal cavity, all omental samples
were immediately washed to ensure no sample dried out and tissue manipulation
was minimised.It is also possible that trauma to the peritoneal mesothelial cell
monolayer occurred during surgery and indeed this is thought to be the
mechanism for development of abdominal adhesions as a complication of
surgery. Data on the timing of collection of omental samples in relation to the
abdominal surgery being performed wasnotrecorded, but it might be appropriate
to ensure that omental samples for HPMCisolation should be collected at the
beginning of the surgical procedure, to reduce the chances of peritoneal trauma
due to the surgical manipulation. In addition to assessing HPMCyield, the data
suggest a trend towards increased fibroblast contamination in method B versus
method C. The differences observed did not reachstatistical significance and
need further corroboration. However these results suggest that the method C for
HPMCisolation (0.25% trypsin for 20 minutes) was superior.
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Invasion into the in-vitro peritoneal model was reproduced using four
different gastrointestinal cancer cell lines, each with different degree of
differentiation and invasion potential. Assessment by light microscopy, using
Haematoxylin eosin and immunocytochemistry techniques allowed to confirm
previously reported findings regarding cancer cell and host mesothelial cell
behaviour. Unlike cancer cells, HMPC behaved as non-invasive cells by lining
the ECM as a monolayer. Although no visible basal membranewasidentified by
immunocytochemistry, HMPC behaved as if a physical barrier between the
monolayer and ECM existed. On the in vitro models, the four cancer cells
showed different patterns of invasion. HT29 cells grew on the mesothelial cell
surface only; invasion did not progress into the extracellular matrix, which
corresponded with this tumour’s well differentiated nature. SW480 was able to
invade and form rudimentary glandular structures wheninitial cell concentration
was 10° cells/ml. This feature was unique to SW480 and confirms observations
previously reported by Jayne et al. (Jayne, O'Leary et al., 1999b). The TMK I
and KATO III cells were visibly demonstrated a more invasive behaviour on
light microscopy. Both cell lines invaded through the mesothelialcell layer. They
could digest the extracellular matrix and form distant metastatic deposits within.
Fibroblasts would typically orientate themselves towards the direction of the
tumour during invasion. These findings had also been previously reported by
Jayne et al. (Jayne, O'Leary et al., 1999b).
Immunocytochemistry allowed further cell characterisation within the
model. All cancercell lines stained positively with epithelial antibodies including
Ber EP4, which is commonly used in clinical practice to stain carcinomacells
such as breast cancer. Although staining intensities varied, overall
characterisation for all epithelial cancer cell lines was satisfactory. Mesothelial
cells from non un-invaded models reproduced the results already stated above.
The fact that Ber EP4 did not stain mesothelial cells confirmed the mesodermal
nature ofthese cells.
The extracellular matrix and basal membrane of normal peritoneum and
invasion models was characterised with vimentin, collagens III and IV as well as
laminin and fibronectin. These results reproduced those published by Jayneet al
(Jayne, O'Leary et al., 1999b) who showed that fibroblasts and extracellular
matrix stained with antibodies such as vimentin, collagens III and IV, laminin
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and fibronectin to varying degrees; however, no physical basal membrane could
be demonstrated. An interesting finding was the presence of staining around
groupsof cancer cells resembling a membraneor capsule. This did not happen in
non invaded mesothelium. TMK model showedthis feature whether stained with
fibronectin, laminin or collagen III but not with collagen IV. Moreover KATOIII
also presented this capsular feature when stained with collagen IV and laminin.
HT 29 modeldid with fibronectin, whereas SW480 models did not demonstrate
this feature at all. Although the significance of this capsular formation was
uncertain, it seemed more common in the most aggressive cancer models. As
mesothelial layers were often destroyed by invading cancer cells and no basal
membrane could be demonstrated in this peritoneal modelit is difficult to define
the relationship between these apparent capsular formations and any pre-existing
basal membrane.
The interest in staining the invasion models with adhesion molecule
related antibodies was based onthe likely relevance of adhesion molecules to the
process of peritoneal metastases. ICAM-1 has been reported to be secreted
locally by tumours (Alexiou, Karayiannakis et al., 2001;Maruo, Gochi etal.,
2002) and suppress immuneresponse. Lymph node and metastatic spread have
been correlated with high serum levels of ICAM-1 in various tumours. Some
authors have suggested a role for serum ICAM-1 as a prognostic factor of the
disease (Maruo, Gochiet al., 2002). ICAM-2 potential for gene therapy has been
reported by Tanakaet al(Tanaka, Yashiroetal., 2004)
Therefore ICAM-1 staining was assessed in all invasion models and
potential correlation between ICAM-1 expression and invasiveness was sought.
Despite current evidence suggesting that ICAM-1 expression has an important
role in development of peritoneal invasion and metastasis, no correlation
between ICAM-1 expression and invasive behaviour was found. These findings
suggested ICAM-1 is always expressedat local level and thus may not be a good
marker of invasiveness of metastases in the gastrointestinal tumours studied here.
Moreover ICAM-1 wasalso expressed by non-invaded mesothelialcells.
VCAM and PECAM did not produce any staining in the majority of
models. These glycoproteins of the immunoglobulin superfamily are commonly
encountered in the surface of endothelia (Parums, Cordell et al., 1990;Wilkinson,
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Edwards et al., 1993). As in vitro models lacked any vasculature these results
were expected.
Laser capture technology was used to collect cancer cells and mesothelial
cells from each model andstudy their transcriptional responses independently.
RNAisolation and amplification was performed and 50 samples of RNA from
cancer cells and neighbouring mesothelial cells were hybridised to commercial
cancer arrays. Successful microarray studies depend on enough good quality
starting material (total RNA) available. RNA yield from cells is variable but 1-
2ug of RNA mayrequire extraction of total RNA from approximately 10°-10°
cells. Acquiring this number of cells was not possible in this or indeed in many
other clinical studies (Li, Adamset al., 2003). Hence it was crucial to identify a
robust amplification protocol which would yield sufficient good quality RNA.
Numerous methods have been published in the literature. The most popular
methods involve either in vitro transcription or SMART technology. Thefirst
described method amplified the RNA through in vitro transcription (IVT),
usually employing reverse transcription and two amplification cycles. This was
first published by Eberwine et al (Eberwine, 1996;Van Gelder, von Zastrow et
al., 1990). Its principle involves the reverse transcription of total RNA using an
Oligo dT primer bearing a T7 promoter and subsequentin vitro transcription of
DNA thus generating thousands of copies of amplified anti-sense or
complementary RNA,using a highly specific T7 RNA polymerase. Although this
was originally described to start with 40ug of total RNA, optimisation of the
protocol throughout the years has made possible to work with far smaller
amounts of starting material. This protocol, now considered by many the gold
standard, is well documented and commercially available. It is possible to
perform subsequent rounds of amplification using random primers and a
modified protocol has been reported to successfully amplify as little material as
RNAfrom single cell (Kamme, Zhuet al., 2004).
Amplification methods based on template switching technology have
grown in popularity. These were developed to solve issues such asstarting
material, reliability of reverse transcription and the need for various rounds of
amplification. As reverse transcription may not always transcribe the entire
mRNAsequence,the 5' ends of genes could to be under-represented in amplified
cDNA.This would often the case for long mRNAs,especially if the first-strand
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synthesis is primed only with oligo (dT) primers. Adding the SMARTprimerto
the reverse transcription reaction has been reported to avoid such 3” bias, thus
making reverse transcription and subsequent amplification more reliable (Seth,
Gorrell et al., 2003a). Amplification starts with nanograms of total RNA and
generates large quantities of double stranded cDNA in a single round without in
theory the need for further rounds (Kenzelmann, Klarenetal., 2004;Seth, Gorrell
et al., 2003b). Thus, where tissue sources cannot provide sufficient amounts of
RNAto proceed to microarray or other techniquesdirectly, validated methods of
amplification are available and some groups have even combinedboth switching
primer technology and T7 amplification (Ji, Zhou et al., 2004) with successful
results.
When the amount of starting RNA is not detectable by conventional
means such as spectrophotometry and its quality cannot be checked,it is crucial
to choose an amplification method that is reliable, reproducible, robust, and
simple. Some authorities have reported successful amplification of RNA from a
single cell (Kelz, Dent et al., 2002). Kammeet al (Kamme, Zhu etal., 2004)
worked with samples containing some 14 captured cells and using a modification
of the protocol from Eberwine (Van Gelder, von Zastrow et al., 1990) they
successfully amplified RNA in two rounds of amplification and hybridised their
samples on cDNAarrays.
Myinitial experiments with switching primer amplification, as described
by BD Biosciences (www.bdbiosciences.com, Oxford, UK), did not yield
satisfactory results. Although a second round using random primers and T7
amplification might have been successful, I was not confident with the results.
Stirewalt et al (Stirewalt, Pogosova-Agadjanyan et al., 2004) developed a
protocol that combined the reproducibility of linear amplification and the
robustness of PCR. Unlike the original SMARTprotocol, here amplification of
DNAtakes place only from the 5’ end producing large amounts of first strand
cDNA. In a separate reaction second strand (complimentary) cDNA is
synthesised. Their method was compared to a modified version of the protocol
by Eberwine (Stirewalt, Pogosova-Agadjanyan et al., 2004). It was concluded
that whilst the reproducibility of both methods wassimilar, the overall reliability
of single linear amplification was superior. The protocol proposed byStirewalt et
al (Stirewalt, Pogosova-Agadjanyanet al., 2004) was used in these studies and
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found to be reliable and reproducible. For the second round of amplification I
used the original protocol from Eberwine (Van Gelder, von Zastrowet al., 1990)
available as the Message Ampkit from Ambion.
Following hybridisation into cancer arrays and microarray analysis as
described earlier it has been possible to demonstrate that 3D models of
peritoneum may provide valuable information about the molecular biology of
peritoneal metastasis. Microarray work in this model has never been donebefore.
The limitations of a 3D model, in terms of lifespan and cellular characteristics,
lead to a limited understanding of the results. The lack of a systemic response to
the disease translated into a more basic understanding of peritoneal metastasis at
the local level. While this may seem incomplete, it may prove advantageous,at
least initially, in a field that is poorly understood.
Invading cancer cells and host mesothelial cells only showeda limited
number of genes with a pattern of expression that could be associated with the
previous microscopic findings. Many functions potentially relevant to the
metastatic process werenotreflected in the results. There were two main reasons
for this. Either a gene or a group of genes were notdifferentially expressed or if
they were, this difference in expression levels was mostly related to one cell
group. For example, cancer cells showed a number ofproteases, or inhibitors
thereof that were differentially expressed in one cell line. This included TIMP-1
and TIMP-2, MMP-17 and cathepsin-k. While they play a crucial role in
invasion, their expression levels in the 3D model only demonstrated significant
differences in the TMKcell line, except for TIMP-2 which had higherlevels in
KATOcells. Host mesothelial cells also failed to demonstrate many genes which
could be relevant to vital functions such as cell to cell adhesion. While tubulins
were shownearlier to be differentially expressed, other genes such as cadherin I
were showed higherlevels of expression in non-invaded peritoneum, TMK and
KATO, compared to SW480 and HT29. Furthermore, non invaded HPMC did
not behave as a baseline model. Often gene expression levels from HMPC were
similar to those of one or more cancercell lines, rather that at the highest or
lowest point of a gradient. The reasons for this were unclear. It is also
acknowledged that the limited choice and availability of cancer cell lines at the
time of these experiments is a source of potential bias. It is not possible to
demonstrate that results obtained were not influence by the nature of thetissues,
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rather than their aggressive behaviour. It is well known that gastric carcinoma
usually behaves very differently from colorectal carcinoma. It would have been
ideal to compare a series of gastric tumours amongst themselves. Alternatively
tumours could have been comparedto healthytissue.
Overall it becomes apparent that further experiments, including more
arrays and more cancercell lines could have provided more robust results. The
initial plan was to perform experiments using slides printed in the laboratory;
howeverthe quality of these in-house printed slides never reached the required
standard, and other arrangements had to be made. Theavailability of many more
microarray slides would have meant more replicates; both biological and
technical. However, commercial slides were costly, seriously compromising the
numberofexperiments,
However the in vitro peritoneal model of peritoneum also had some
limitations. While valuable information could be gained aboutthe early stages of
invasion of the in vitro models, these were removed from culture after a given
numberof days. Subsequently any information gained would be based on a given
point in time, thus missing changesovera period. If models could survive weeks
or months, a more thorough study of peritoneal metastasis during various stages
of the disease could be possible. Moreover, only three cell types were present in
the model. There were no vessels, no blood supply, no immune system, which
translated into a lack of ability to generate a systemic response to invasion,asit
would take place in humans. Therefore, some functions which take place at the
very local level, such as disruption of HPMC adhesion and proteolysis of the
extracellular matrix may be reproduced in an in vitro model, whereas the
understanding of those functions provided by a host response such as immunity,
angiogenesis, cell repair or apoptosis maybelimited.
With regards to the RT PCR, genes relevant to apoptosis, ECM
proteolysis and cytoskeletal disruption were tested. The results presented showed
that an alternative test could potentially confirm the microarray findings. While
negative results were obtained, further experiments with both microarrays and
RT PCR could have shown more conclusiveresults.
Howeverit should also be remembered that there are other reasons why
the real-time PCR results may differ from those of the microarrays.
Normalisation of results from the PCR experiments was performed using
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GAPDHasa single reference gene. This assumesthat the expression ofthis
gene is constant in all cells tested, and if this assumption holds then
normalisation can be performed to correct for different amounts of starting RNA.
Unfortunately, though genes such as GAPDHare expressed as high level by
most cells, there is evidence that expression of this gene varies in different
conditions and in different cell types (Pfaffl, Tichopad et al., 2004). Hence
reliance on expression of a single gene such as GAPDHto help normalise
another gene’s expression may well lead to spurious results due to alteration in
expression of GAPDHitself. If further RT PCR experiments were possible, this
problem could be avoided by using several genes as reference or normalisation
genes and using an average of the combined expression as the normalisation
factor (Pfaffl, Tichopadet al., 2004).
Finally, research on peritoneal metastases could be further expanded by
studying particular aspects of the molecular biology. For instance gene
expression relevant to a given cell function could be further assessed using
custom arrays with related genes. Whilst it may be argued that many cellular
functions interact with others, rather than working independently, a thorough
study of individual functions could provide more answers than a more general
approach.
A disadvantage of any in vitro modelis the lack of systemic response to
the environment provided by molecules from other cells and organs. A possible
avenue for future research could be the incubation within the ECM ofendothelial
cells and investigation of their ability to form vascular structures. This would
give the 3D model a closer resemblance to human peritoneum. Endothelial cells
may secrete chemoattracting molecules and angiogenic factors and their role
could potentially provide better understanding aboutlocal peritoneal response to
pathological events such as inflammation, adhesionsor neoplasia.
Furthermore, a three dimensional model of peritoneum could also be
useful for the assessment of gene functions during invasion. Thus, known genes
could be tested in the models by introducing silencing RNA sequences into
cancer cells, allow invasion to take place and compare behaviour with non
treated models.
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13. APPENDICES
138
3D
IN
VA
SI
ON
MO
DE
LS
Mo
de
l
Nu
mb
er
Mo
de
l
Nu
mb
er
Ka
to
10
4c
§
Ka
to
10
5c
31
Ka
to
10
4m
6
Ka
to
10
5m
32
Ka
to
10
5c
7
Ka
to
10
6c
33
Ka
to
10
5m
8
Ka
to
10
6m
34
Ka
to
10
6c
9
SW
48
01
04
c
35
Ka
to
10
6m
10
SW
48
01
04
m
36
SW
48
01
04
c
11
SW
48
01
05
c
37
SW
48
01
04
m
12
SW
48
01
05
m
38
SW
48
01
05
c
13
SW
48
01
06
c
39
SW
48
01
05
m
14
SW
48
01
06
m
40
SW
48
01
06
c
15
HT
29
10
4c
41
SW
48
01
06
m
16
HT
29
10
4m
42
HT
29
10
4c
17
HT
29
10
5c
43
HT
29
10
4m
18
HT
29
10
5m
44
HT
29
10
5c
19
HT
29
10
6c
45
HT
29
10
5m
20
HT
29
10
6m
46
HT
29
10
6c
21
TM
K1
04
c
47
HT
29
10
6m
22
TM
K1
04
m
48
TM
K1
04
c
23
TM
K1
05
c
49
TM
K1
04
m
24
TM
K1
05
m
50
TM
K1
05
c
25
TM
K1
06
c
51
TM
K1
05
m
26
TM
K1
06
m
52
TM
K1
06
c
27
pe
ri
to
ne
um
53
TM
K1
06
m
28
Neg
co
nt
ro
l
54
Ka
to
10
4c
29
pe
ri
to
ne
um
55
Ka
to
10
4m
30
Ta
bl
e
16
50
mo
de
ls
of
pe
ri
to
ne
um
we
re
ma
de
.
Wi
th
in
th
e
mo
de
l
co
lu
mn
,l
et
te
rs
“c”
an
d
“m
”
in
di
ca
te
wh
et
he
r
can
cer
ce
ll
s
or
me
so
th
el
ia
l
cel
ls
we
re
las
er
ca
pt
ur
ed
.
Nu
mb
er
s
10
4,
10
5
an
d
10
6
co
rr
es
po
nd
ed
to
the
ini
tia
lc
onc
ent
rat
ion
s
of
inv
adi
ng
ca
nc
er
cel
ls
(1
04
=1
04
cel
ls/
ml,
10
5=
10
5
cel
ls/
ml,
10
6=
10
°
cel
ls/
ml)
.
Wi
th
in
th
e
nu
mb
er
co
lu
mn
ea
ch
nu
mb
er
is
a
un
iq
ue
ide
nti
fie
r f
or
ea
ch
mo
de
l
139
13.1 REFERENCE RNA AMPLIFICATION DATA
 
Name TotalRNAng A260 A280 Ratio aRNAypg/pl Total aRNA
(ug in 100!)
A1X 1000 0.387 0.203 1.906404 0.8514 85.14
A2X 1000 0.264 0.139 1.899281 0.5808 58.08
A3X 1000 0.356 0.185 1.924324 0.7832 78.32
B1xX 100 0.505 0.262 1.927481 1.111 111.1
B2xX 100 0.413 0.216 1.912037 0.9086 90.86
B3xX 100 0.374 0.201 1.860697 0.8228 82.28
C1X 10 0.386 0.201 1.920398 0.8492 84.92
C2X 10 0.258 0.118 2.186441 0.5676 56.76
C3X 10 0.334 0.178 1.876404 0.7348 73.48
F1X 1 0.354 0.187 1.893048 0.7788 77.88
F2X 1 0.243 0.13 1.869231 0.5346 53.46
F3X 1 0.361 0.188 1.920213 0.7942 79.42
M2x 0.1 0.273 0.137 1.992701 0.12012 12.012
M3X 0.4 0.22 0.122 1.803279 0.0968 9.68
X1X 0.01 0.199 0.105 1.895238 0.08756 8.756
X3X 0.01 0.23 0.127 1.811024 0.1012 10.12
Y1X 0.001 0.105 0.051 2.058824 0.0462 4.62
Y2X 0.001 0.171 0.094 1.819149 0.07524 7.524
 Table 17 Amplification performed with Reference RNAat various concentrationsof starting
material. Below Ing of total RNA, amplification values fell dramatically
13.2 RNA SPECTROPHOTOMETRY BEFORE Cy LABEL
 
A) PERITONEAL MODELS
A260 A280 Ratio Start pg/pl Start total
MEAN 0.54 0.27 2.01 1.19 113.50
ST DEV 0.12 0.06 0.16 0.26 24.43
RANGE 0.26-0.68 0.13-0.36 1.8-2.45 0.56-1.49 53.3-141.08
B) REFERENCE RNA
A260 A280 Ratio Start pg/pl Start total
MEAN 0.34 0.18 1.90 0.74 70.41
ST DEV 0.07 0.04 0.09 0.16 15.40
RANGE 0.26-0.58 0.14-0.3 1.80-2.14 0.56-1.28 53.50-121.85
Tables 18 A,B Each variable wasexpressedin the following units: pg/l, start total
ug/100ul
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13.3 CLASS COMPARISON STUDIES FOR HOST
MESOTHELIAL CELLS
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13.5 RT PCR DATA
13.5.1 CATHEPSIN K
Tables 23 A,B Ct values and ratios for cathepsin K expression in host
mesothelial cells (A, samples; B, reference RNA)
 
A)
Host mesothelial cells Ct. CathepsinK GAPDH Ratio Cell group Statistics Values
HT 29 22 23.26 22.56 1.03 HT 29 Mean 1.03
HT 29 22 22.57 22.40 1.01 ST 0.02
HT 29 22 23.12 22.26 1.04
Kato 10 29.14 18.82 1.55
Kato 10 29.32 18.91 1.55
Kato 10 28.91 18.82 1.54 KATO Mean 1.40
Kato 34 28.41 22.42 1.27 ST 0.16
Kato 34 28.18 22.32 1.26
Kato 34 28.08 22.63 1.24
peritoneum 55 28.24 24.81 1.14 peritoneum Mean 1.18
peritoneum 55 28.51 24.84 1.15 ST 0.03
peritoneum 55 28.86 2466 1.17
peritoneum53 25.6 21.05 1.22
peritoneum53 25.52 21.04 1.21
peritoneum53 25.37 20.97 1.21
SW480 16 19.58 22.59 0.87 SW 480 Mean 1.07
SW480 40 25.75 22.44 1.15 ST 0.14
SW480 40 25.45 22.34 1.14
SW480 40 26.12 22.97 1.14
TMK 28 25.7 23.65 1.09 TMK Mean 1.27
TMK 28 25.92 23.90 1.08 ST 0.17
TMK 52 27.08 18.94 1.43
TMK 52 26.82 19.63 1.37
TMK 52 27.02 19.52 1.38
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Reference RNA Dilutions CathepsinK GAPDH Ratio Statistics Values
2 D2 0.5 25.06 19.49 1.29
3 D3 0.2 25.24 20.44 1.23
4 D4 0.1 25.86 21.95 1.18 Mean 1.21
5 D5 0.05 26.69 22.6 1.18 ST 0.05
6 D6 0.02 27.73 23.57 1.18
7 D7 0.01 28.27 24.52 1,45
8 D8 0.005 30.36 26.07 1.16
10 D2 0.5 23.84 18.3 1.30
11 D3 0.2 25.77 20.36 1.27
12 D4 0.1 26.97 21.45 1.26
13 D5 0.05 27.1 22.19 1.22
14 D6 0.02 27.62 23.24 1.19
15 D7 0.01 29.21 24.45 1.19
16 D8 0.005 30.39 25.58 1.19
18 D2 0.5 24.21 18.73 1.29
19 D3 0.2 25.62 20.3 1.26
20 D4 0.1 26.46 21.47 1.23
21D5 0.05 27.03 22.06 1.23
22 D6 0.02 28.03 23.5 1.19
23 D7 0.01 28.85 24.62 1.17
24 D8 0.005 29.91 25.65 1.17
25 D9 0.002 31.42 27.04 1.16
26 D9 0.002 31.76 27.52 1.15
27 D9 0.002 31.41 26.98 1.16
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13.5.2 VIMENTIN
Tables 24 A,B Ct values and ratios for vimentin expression in host mesothelial
cells (A, samples; B, reference RNA)
 
 
Reference RNA Dilutions Vimentin GAPDH Ratio Statistics Values
2 D2 0.5 19.13 17.83 1.07
3 D3 0.2 20.62 19.47 1.06
4D4 0.1 21.05 19.46 1.08
5D5 0.05 22.24 20.98 1.06 Mean 1.07
6 D6 0.02 22.52 21.31 1.06 ST 0.01
7 D7 0.01 23.95 22.26 1.08
8 D8 0.005 24.45 23.3 1.05
10 D2 0.5 18.77 17.48 1.07
11 D3 0.2 19.72 18.52 1.06
12 D4 0.1 20.69 19.53 1.06
13 D5 0.05 21.76 20.51 1.06
14 D6 0.02 22.65 21.29 1.06
15 D7 0.01 23.65 22.3 1.06
16 D8 0.005 25.57 23.29 1.10
Negative control 39.43 0
Host mesothelial cells Vimentin GAPDH Ratio Cellgroup Statistics Values
HT 29 22 20.77 20.52 1.01 HT29 Mean 1.02
HT 29 22 20.92 20.19 1.04 ST (*)
Kato 10 21.28 17.17 1.24 Kato Mean 1.21
Kato 10 20.64 16.97 1.22 ST 0.02
Kato 34 22.91 19.16 1.20
Kato 34 24.04 20.11 1.20
SW480 16 21.55 19.73 1.09 SW480 Mean 1.10
SW480 16 21.2 19.94 1.06 ST 0.03
SW480 40 22.93 20.29 1.13
SW480 40 22.8 20.63 1.11
TMK 28 22.54 21.38 1.05 TMK Mean 1.05
TMK 28 22.16 21.03 1.05 ST 0.02
TMK 52 18.48 17.23 1.07
TMK 52 18.12 17.54 1.03
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